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Abstract  
Blood protein diagnostics has the potential to revolutionize health care by 
providing the relevant clinical measurements that can provide the foundation for 
predictive, preventive, and personalized medicine.1 Blood bathes all organs in the body, 
with a circulation time of just a few minutes.2 Those organs secrete proteins into the 
blood, some of which contain information relevant to the health or disease status of the 
organ.3–5 Thus, the blood potentially provides a window into the health state of each 
individual, and the organ-specific secreted proteins can provide a molecular fingerprint of 
disease.  The hypothesis is that each organ (and its associated diseases) has a unique 
fingerprint that can be read from the blood with an appropriately multiplexed diagnostic 
platform.  These fingerprints potentially provide insight that can be harnessed for early 
disease diagnostics, since the protein levels associated with the organ-specific fingerprint 
will be altered by the onset of disease and by the stages of disease progression.  A 
challenge is that capturing each organ-specific blood fingerprint will require the 
assessment of the levels of many blood protein biomarkers. Capturing the fingerprint 
from all of the 50 or so major organs (or organ regions) may require the measurement of 
from several hundred to a thousand or more proteins. Meeting such a challenge requires 
new technologies at all levels— from devices designed to process and deliver the blood 
proteins for measurement,2,6,7 to sensitive measurement approaches,8–12 to affinity agents 
that can be utilized to capture the relevant biomarker proteins,13–17 to computational 
approaches that can process large numbers of measurements into a result that can be 
interpreted by a physician.3,4,18–20  
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 To realize this vision of personalized healthcare, disease diagnostics 
measurements must be extremely inexpensive.  Currently the assessment of blood-based 
protein biomarkers can take from between several hours to several days, depending upon 
the resources of a specific healthcare clinic.  Consider, for example, a prostate-specific 
antigen (PSA) ELISA (enzyme-linked immunosorbent assay) test that helps detect 
prostate cancer in men.21 In this test, a patient's serum is diluted and applied to a plate to 
which PSA antigens have been attached. If antibodies to PSA are present in the serum, 
they may bind to these PSA antigens. The plate is then washed to remove all other 
components of the serum. A specially prepared "secondary antibody" — an antibody that 
specifically binds to human antibodies — is then applied to the plate, followed by another 
wash. Prior to this step, the secondary antibody is chemically linked to an enzyme. Thus, 
after application of the secondary antibody, the plate will contain immobilized enzyme in 
proportion to the amount of secondary antibody bound to the plate. A substrate for the 
enzyme is applied, and catalysis by the enzyme leads to a change in color or 
fluorescence. ELISA results are reported as a number; the most subjective aspect of this 
test is determining the "cut-off" point between a positive and negative result. This ELISA 
assay is representative of a typical test for a protein biomarker but it does have its 
disadvantages.  First, it requires large amounts (~ 5–10 ml) of blood to be collected from 
the patient.  Second, the long time period separating the point of blood collection from 
the time of measurement has associated costs in terms of both measurement accuracy 
(degradation of blood-based proteins) and labor costs.  Third, the antibodies that serve as 
protein capture agents are expensive to develop, purchase, and store, and can be degraded 
by any number of subtle physical, chemical, and biological influences.   Fourth, most 
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diagnostics measurements are pauciparameter.  Fifth, the sensitivity, specificity, and/or 
dynamic range of the biomarker detection strategies are often limited.    
 In this thesis, I describe projects that were aimed at addressing specific aspects of 
some of these problems. Nanoelectronic sensors, such as silicon nanowires (SiNWs), 12,22 
can provide quantitative measurements of protein biomarkers in real time. Another 
advantage of SiNWs is that they are label-free sensors, so no secondary antibody is 
needed to detect the binding event. The goal is to fabricate large arrays of SiNW circuits, 
each of which can be individually functionalized by a different capture agent.  When the 
blood protein binds to the specific capture agent, both the electrical conductance of the 
nanowire and the electrical capacitance between the nanowire and the serum is changed.  
These changes correlate to the amount of the protein in the blood, and thus permit a label-
free, real-time measurement.  One technical challenge for nanoelectronic protein sensors 
is to develop chemistry that can be applied for selectively encoding the nanowire surfaces 
with capture agents, thus making them sensors that have selectivity for specific proteins 
or other biomolecules.  Furthermore, because of the nature of how the sensor works, it is 
desirable to achieve this spatially selective chemical functionalization without having the 
silicon undergo oxidation.  The native oxide on silicon (SiO2) has a low isoelectric point, 
meaning that under physiological conditions (= pH 7.4), surfaces are negatively 
charged.23 These surface charges can potentially limit the sensitivity of certain 
nanoelectronic biomolecular sensor devices through Debye screening of the biomolecular 
probe/target binding event to be sensed.  Furthermore, the native oxide of Si can 
detrimentally impact carrier recombination rates.24 For high-surface-area devices, such as 
SiNWs, this can likely result in a degradation of electrical properties.   
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A general method for the non-oxidative functionalization of single-crystal silicon 
(111) is described in Chapter 1.  The general approach is to start with a silicon-on-
insulator (SOI) wafer.  A SOI wafer is comprised of a thin, single-crystal silicon film  
(~ 30–50 nm) on top of a thick, insulating SiO2 layer (on the order of microns).  It is from 
this SOI layer that the nanowire sensors are fabricated.  The silicon film, unless specially 
treated, is naturally passivated with a thin (1–2 nm thick) native oxide (SiO2) layer as 
described above. To remove the native oxide, the silicon surface is fully acetylenylated  
(-C≡CH), thus preventing the growth of oxidation.  Additionally, the -C≡CH group also 
provides a chemical handle for additional functionalization via the ‘click’ reaction25,26 
between an azide containing benzoquinone (masked with a primary amine) and the 
surface-bound alkyne.  The benzoquinone is electrochemically reduced, exposing the 
amine terminus. During this process, minimal oxidation is present.  Molecules presenting 
a carboxylic acid have been immobilized to the exposed amine sites.  This strategy 
provides a general platform that can incorporate organic and biological molecules on Si 
(111) with minimal oxidation of the silicon surface.  This method can further be extended 
towards the selective biopassivation of capture agent arrays of nanoelectronic sensor 
devices.  
The development of these devices is, in part, driven by early diagnosis, 
differential treatment, monitoring, and personalized medicine— all of which are 
increasingly requiring quantitative, rapid, and multiparameter measurement capabilities 
on ever smaller amounts of tissues, cells, serum, etc.1–5 To begin achieving this goal, a 
large number of protein biomarkers need to be captured and quantitatively measured to 
create a diagnostic panel. One of the greatest challenges towards making protein-
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biomarker-based in vitro diagnostics inexpensive involves developing capture agents to 
detect the proteins.  In the content of this thesis, a capture agent is a biochemical 
molecule that has specificity for a distinct target molecule and can be naturally derived 
and/or synthetic.  A major thrust of this thesis is to develop multi-valent, high-affinity 
and high-selectivity protein capture agents using in situ click chemistry.27–30 In situ click 
chemistry is a tool that utilizes the protein itself to catalyze the formation of a biligand 
from individual azide and alkyne ligands that are co-localized.  Large libraries of peptides 
are used to form the body of these ligands, also providing high chemical diversity and 
protease stability, with minimal synthetic effort.  Peptide-based moderate-affinity lead 
compounds can be isolated from a 2-generation screen of the protein against a one-bead 
one-compound (OBOC) library.  By modifying that peptide with appropriate alkyne or 
azide functionalities, that peptide becomes an anchor (1°) ligand, and part of the capture 
agent. Simultaneously screening the protein against this single anchor ligand and a large 
library of click-complementary secondary (2°) ligands constitutes our strategy for 
identifying biligand capture agents. The protein target holds the two peptide-units in 
close proximity promoting the covalent coupling between the azide and alkyne moieties.  
This process can be repeated— the biligand capture agent can serve as the new anchor 
unit and the same OBOC library can be employed to identify a triligand, tetraligand, and 
so forth. The addition of each ligand to the capture agent causes the affinity and 
selectivity to increase dramatically for its cognate protein.  In particular, we describe the 
production of a triligand capture agent that exhibits 45 nM and 64 nM affinities against 
human and bovine carbonic anhydrase II (bCAII and hCAII) protein, respectively, and 
can be used in a dot blot test to detect those proteins at the ≥ 20 ng level from 10% 
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serum.  In situ click chemistry screens are shown to yield results identical to more 
traditional OBOC screens, but the in situ screens permit orders of magnitude more 
chemical space to be sampled. Moreover, the resulting multiligand protein capture agents 
can be produced in gram-scale quantities using conventional synthetic methods with 
designed control over chemical and biochemical stability and water solubility.  
Chapter 2 will cover the synthesis of the azide containing artificial amino acids at 
the multi-gram quantity scale.  The construction of large (up to 20 million elements on 
100 million beads) peptide libraries for screening, including bulk peptide synthesis and 
on-bead click reaction will be discussed.  Bead-based library screening procedures will 
be reviewed.  Analysis of lead compounds by Edman degradation will be introduced, 
including calibrating peptide-sequencing equipment so artificial amino acids can be 
identified. 
Chapter 3 will cover screening procedures and results for the anchor ligand, 
biligand, and triligand in detail.  Binding affinity measurements using fluorescence 
polarization and surface plasmon resonance (SPR) are reported. The sensitivity and 
selectivity of the multi-ligand (biligand and triligand) capture agents for CAII proteins in 
complex environments are demonstrated through the use of dot blot experiments in 10% 
serum.  The advances of this approach are multifold and will be discussed in Chapter 3. 
This is a general and robust method for inexpensive, high-throughput capture agent 
discovery that can be utilized to capture the relevant biomarker proteins for blood protein 
diagnostics.  
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1.1 Introduction  
Semiconductor devices and semiconductor processing are playing an increasingly 
large role in biotechnology, with applications that include nanowires (NWs)1 and 
nanocantilevers2,3 for label-free biomolecular sensors, nanofluidics for biomolecular 
separations,4–7 and a host of microfabricated lab-on-a-chip technologies.8,9  Coupled with 
these emerging nano- and microtechnologies has been the emergence of mechanical,10–12 
chemical, and electrochemical approaches for functionalizing and/or selectively 
activating surfaces.  Electrochemical activation of surfaces is particularly relevant since it 
is shape conformal and is only limited by the size of electronically addressable features 
(which can be much denser than what can be spotted with an inkjet, for example).  
Electrochemical activation of metal surfaces has been pioneered by Mrksich,13–16 and 
applications of that chemistry towards the biofunctionalization of semiconductor 
nanowires has been demonstrated by at least two groups.17,18  For Si surfaces, the 
chemistry is particularly challenging: without protection, Si will form a native oxide that 
can prevent the use of silicon electrodes for electrochemical functionalization.  The 
native oxide on silicon also has a low isoelectric point, meaning that under physiological 
conditions (= pH 7.4), SiO2 surfaces are negatively charged.19 These surface charges can 
potentially limit the sensitivity of certain nanoelectronic biomolecular sensor devices 
through Debye screening20 of the biomolecular probe/target binding event to be sensed.  
Furthermore, the native oxide of Si can detrimentally impact carrier recombination 
rates.21 For high-surface-area devices, such as Si NWs, this can likely result in a 
degradation of electrical properties.  Thus, the ideal biofunctionalization strategy for 
electrochemically activating Si surfaces should begin with non-oxidized Si.  The 
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approach should also provide continued protection of the Si surface against subsequent 
oxidation, and should limit the number of surface traps that can increase carrier 
recombination rates. 
Several methods for attaching organic molecules onto non-oxidized Si surfaces 
have been reported.  One class of schemes relies upon the direct covalent attachment of 
alkene-terminated molecules to H-terminated surfaces by thermal induction, ultraviolet 
(UV) light, or catalysis.22–29 These strategies have not been demonstrated as giving long-
term protection to the Si surface against oxidation.  Lewis’ group has developed the two-
step chlorination/alkylation procedure for Si(111) surfaces that is based upon Grignard 
chemistry.30–35  A limitation of these approaches is that only the methylated Si(111) 
surface (using Lewis’ chemistry) can be 100% covered.31,36  For example, the coverage 
that can be achieved through the ethylation of Cl-terminated Si(111) is limited by steric 
affects and is about 80% of the atop sites.37  For larger organic molecules, surface 
coverages will most certainly be lower, and resistance to oxidation reduced.  In order to 
fully passivate the Si(111) surface, generate resistance to oxide growth, and provide for a 
chemically versatile surface, different surface chemistries are needed.  Recently, J. J. 
Gooding has made passivated Si(100) surfaces using hydrosilylation and bis-alkyne for 
much more technologically relevant Si(100) surface against oxidation.38   
Chapter 1 describes a versatile and robust strategy for chemically passivating 
Si(111) surfaces in a manner that stabilizes the underlying Si against oxidation and 
allows for both chemical and electrochemical functionalization of the surface.  Based 
upon our previous work on methylated and ethylated Si(111),30–37 we chose to explore the 
more chemically versatile acetylenylation (-C≡CH) of chlorine-terminated Si(111).  
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Work by Nemanick39 and Lewis’ group40,41 indicated that the chlorination/alkylation 
chemistry for acetylenylating Si(111) could proceed to completion.  The footprint of the 
-C≡CH on Si(111) should be as small or smaller than the –CH3 group, and so a high 
surface coverage should be possible.  Equally important is that the -C≡CH group also 
provides a chemical handle for additional functionalization via the Cu(I) catalyzed 
Huisgen 1,3-dipolar cycloaddition (‘click’ reaction42,43) between an azide and the surface-
bound alkyne to form a 1,4-disubstituted 1,2,3-triazole (Scheme 1.1).  
R1 H
N
N
N
R2
N
NN
R2
R1
Cu(I) catalyst
+
-
+
 
Scheme 1.1 Click reaction, leading to the formation of a 1,2,3-triazole 
 
In particular, we designed an azide-functionalized, modified benzoquinone for 
attachment, via the click reaction, to the surface-bound acetylenyl groups to form a 1,2,3-
triazole.  The click reaction is useful because azides and acetylenes are synthetically easy 
to introduce, compatible with a variety of solvents and species, and tolerant against other 
functionality (highly specific, coupling can only occur between these two groups).  Our 
work here follows reports that have demonstrated that different molecules can be clicked 
onto gold and SiO2 surfaces in a variety of solvent and pH conditions.44–52 
We previously reported on the electrochemistry of hydroquinones on Si(111) and 
Si(100) surfaces, attached via the UV-activation of H-terminated Si.17  In that work, the 
hydroquinones could be reversibly oxidized to form benzoquinones (the ‘activated’ 
surface) which could then react by way of either Diels-Alder cycloaddition13,15 or 
Michael addition chemistries,53,54 leading to a selectively biofunctionalized Si microwire 
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or nanowire surface.  However, while the hydroquinone coverage on the Si(111) surface 
did yield at least some protection for that surface against oxidation, the electrochemical 
step to oxidize the hydroquinone also led to oxidation of the underlying Si(111).  Thus, in 
this work, we have designed and synthesized a benzoquinone that can be clicked onto the 
acetylenylated Si surface.  The surface-bound benzoquinone may be then activated via 
electrochemical reduction to produce an amine terminus.  We demonstrate that the entire 
chemical process may be accomplished in a fashion that greatly reduces the oxidation of 
the underlying Si.  We also demonstrate the selective attachment of ferrocene onto an 
electrochemically activated Si(111) surface, as well as the model biomolecule, biotin.   
1.2 Experimental Methods 
1.2.1 Chemicals 
 Anhydrous methanol and anhydrous tetrahydrofuran (THF, inhibitor-free) were 
obtained from Aldrich and exclusively stored and used in a N2(g)-purged glove box.  
Chlorobenzene, benzoyl peroxide, and sodium acetylide (18 wt% in xylenes/light mineral 
oil) were purchased from Aldrich and were stored and used in the glove box.  Phosphorus 
pentachloride (PCl5) was acquired from Riedel-de Haën (Seelze, Germany).  The 40% 
NH4F(aq) solution was obtained from Transene Co. (Rowland, MA) and was used as 
received.  The CuSO4·5H2O was obtained from Spectrum Chemical Mfg. Corp. 
(Gardena, CA).  Sodium ascorbate, ferrocene carboxylic acid, and anhydrous N,N-
dimethylformamide (DMF) were obtained from Aldrich.  N,N′-Diisopropylcarbodiimide 
(DIC) was purchased from Anaspec (San Jose, CA).  Dulbecco’s Phosphate Buffered 
Saline (DPBS) (2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 8 mM Na2HPO4) pH 7.4 
was purchased from Sigma.  EZ-Link NHS-Biotin was obtained from Pierce 
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Biotechnology, Inc. (Rockford, IL).  Nanogold Streptavidin was purchased from 
Invitrogen (Carlsbad, CA).  GoldEnhance-EM kit for Nanogold amplification was bought 
from Nanoprobes (Yaphank, NY). 
1.2.2 Acetylenylation of Si(111)  
Scheme 1.2 shows the strategy used for functionalization of Si(111), using a two-
step chlorination/alkylation method followed by Cu(I)-catalyzed click chemistry.  The 
acetylene passivation leads to a high coverage of atop sites on an unreconstructed Si(111) 
surface (97 ± 5 %), which resists native oxidation of the surface.40,41  Another advantage 
is the ability to use the terminal alkyne to attach a variety of molecules via click 
chemistry. 
 
Scheme 1.2 Strategy for the functionalization of Si(111) 
 
The starting surfaces used in these experiments were single-crystal, polished 
Si(111) wafers, that were 500–550 µm thick, phosphorus-doped (n-type), with 0.005–
0.02 Ω-cm resistivity, and a miscut angle of 3–4° (Montco Silicon Technologies, Spring 
City, PA).  Prior to use, the Si wafers (1 cm × 1 cm) were cleaned by successive 
sonications in acetone, methanol, and isopropanol.  Substrates were then rinsed with 
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Millipore (18 MW) water and then placed into basic piranha solution (5:1:1 = 
H2O:H2O2:NH4OH  warning: caustic!) at 80 °C for 5 min.  The samples were removed 
from piranha solution, rinsed with copious amounts of Millipore water and dried under 
streaming N2(g).  The samples were immediately place in degassed NH4F(aq) solution for 
15 min.  The samples were subsequently removed from the NH4F(aq), rinsed copiously 
with water, dried under streaming N2(g), and immediately loaded into a glove box. 
Chlorination of the Si(111) surfaces (Scheme 1.2, Step 1) was carried out in a 
N2(g)-purged glove box, according to published methods.30–37  A saturated solution of 
PCl5 in chlorobenzene was prepared and heated for one hour prior to use to ensure 
complete dissolution of the PCl5.  To 2 ml of this PCl5 solution, the Si substrate was 
added with a grain of benzoyl peroxide.  The solution was heated to 90 °C for 50 min.  
Subsequently, the samples were rinsed with anhydrous THF several times and 
immediately used for the acetylenylation step. 
Acetylenylation of the chlorinated Si(111) surfaces (Scheme 1.2, Step 2) was 
performed inside the N2(g)-purged glove box.  The chlorinated wafers were immersed in 
a sodium acetylide (18 wt% in xylenes/light mineral oil) suspension and heated to 130 °C 
for 5 hours.41 After reaction, the samples were removed from solution, rinsed copiously 
with anhydrous THF, and then rinsed with anhydrous methanol.  The samples were then 
immersed into a fresh volume of anhydrous methanol, taken out of the glove box into air, 
sonicated for 10 min, and then dried in a stream of N2(g). 
1.2.3 Synthesis and Attachment of Electroactive Benzoquinone   
Scheme 1.3 describes the synthetic procedure for making the electroactive 
benzoquinone 1 used for all surface click reactions.  A 2,3,5-trimethylhydroquinone was 
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treated with dimethylacrylic acid to give a lactone (a) by a Friedel-Crafts type addition 
reaction.  The quinone acid (b) was prepared by oxidation of the resulting lactone (a) 
with aqueous N-bromosuccinimide (NBS).  The acid was activated with an N-
hydroxysuccinimidyl (NHS) group to give (c), which was then subjected to 3-
azidopropylamine to afford 1. 
 
Scheme 1.3 Synthesis of electroactive benzoquinone 
 
6-Hydroxy-4,4,5,7,8-peptamethyl-chroman-2-one (a).  2,3,5-
Trimethylhydroquinone (2 g, 13.1 mmol) was mixed with 3,3-dimethylacrylic acid (1.45 
g, 14.5 mmol) and methanesulfonic acid (10 ml).  The mixture was stirred at 85 °C under 
nitrogen for 3 hours and then cooled to room temperature.  To the mixture was added 100 
g of ice with stirring.  The precipitate was extracted with ethyl acetate (4 × 50 ml).  The 
combined organic layer was washed with saturated NaHCO3 (2 × 50 ml) and water (2 × 
50 ml), and dried over MgSO4.  After filtration and evaporation, an obtained residue was 
recrystallized from hexane and ethyl acetate (2:1, v/v) to give 2.6 g (84%) of the desired 
product as a white solid.  1H NMR 300 MHz (CDCl3) δ 4.69 (s, 1H), 2.56 (s, 2H), 2.37 (s, 
3H), 2.23 (s, 3H), 2.9 (s, 3H), 1.46 (s, 6H). 
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3-Methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid (b).  
To a solution of the lactone a (1.58 g, 6.74 mmol) in a mixture of acetonitrile (15 ml) and 
water (3 ml) was added N-bromosuccinimide (1.26 g, 7.08 mmol) in portions with 
stirring at room temperature. After 30 min, the organic solvents were evaporated under 
reduced pressure, and the remaining solution was extracted with CH2Cl2 (2 × 30 ml).  
The combined organic layer was dried over MgSO4, and reduced solvent to give 1.65 g 
(98%) of a yellow oily product, which was used without further purification.  1H NMR 
300 MHz (CDCl3) δ 3.04 (s, 2H), 2.15 (s, 3H), 1.96 (m, 3H), 1.94 (m, 3H), 1.45 (s, 6H). 
3-Methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid, N-
hydroxysuccinimidyl ester (c).  To a solution of acid b (326 mg, 1.30 mmol) and N-
hydroxysuccinimide (152 mg, 1.32 mmol) in CH2Cl2 (15 ml), was added 1,3-
dicyclohexylcarbodiimide (DCC, 270 mg, 1.31 mmol) portionwise, followed by a 
catalytic amount of N,N-dimethylaminopyridine (DMAP).  The reaction mixture was 
stirred for 1 hour.  The white precipitate was filtered and the filtrate was concentrated.  
The residue was redissolved in cold ethyl acetate (5 ml) and insoluble impurities were 
filtered.  Solvent was removed to give 419 mg (93%) of a yellow foamy solid product.  
1H NMR 300 MHz (CDCl3) δ 3.27 (s, 2H), 2.77 (s, 4H), 2.15 (s, 3H), 1.94 (s, 6H), 1.51 
(s, 6H).  
N-(3-azidopropyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl) 
butanamide (1).  To a solution of c (443 mg, 1.28 mmol) in DMF (5 ml) was added 
diisopropylethylamine (DIEA, 523 ml, 3.06 mmol), followed by 3-azidopropylamine 
(153 mg, 1.53 mmol).  The reaction mixture was stirred overnight at 50 °C, diluted with 
ethyl acetate (30 ml), washed with NH4Cl and brine, and dried over MgSO4.  Solvent was 
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reduced and the residue was purified by silica gel chromatography (hex/EtOAc, 2:1) to 
give 370 mg (87%) of product as a yellow solid.  1H NMR 300 MHz (CDCl3) δ  3.30 (t, J 
= 6.6, 2H), 3.23 (q, J = 6.6, 2H), 2.81 (s, 2H), 2.12 (s, 3H), 1.96 (m, 3H), 1.94 (m, 3H), 
1.70 (quint, J = 6.6, 2H), 1.41 (s, 6H). Mass (ES) m/z 333.0 ([M+1]+). 
Click reaction to attach 1 onto acetylene-terminated Si(111).  The click 
reaction of acetylene-terminated Si(111) (Scheme 1.2, Step 3) with 1 (Scheme 1.3) was 
carried out in anhydrous DMF.  Relative to the azide, 20 mol% sodium ascorbate was 
added, followed by 10 mol% of CuSO4·5H2O, and a 10 mM azide solution of 1 in DMF.  
The reaction was run for 12 hours in the glove box.  After the reaction, the surface was 
sonicated in DMF for 5 min three times and then rinsed with methanol and blow dried 
under N2(g). 
1.2.4 Electrochemical Activation and Attachment 
Ferrocene.  1 was attached to acetylene-terminated Si(111) using the Cu(I)-catalyzed 
click reaction (Scheme 1.2, Step 3), to form 1s (Scheme 1.4).  Reductive electrochemistry 
(–800 mV referenced to Ag/AgCl) was performed to convert the modified benzoquinone 
to hydroquinone in degassed DPBS (pH 7.4).  The hydroquinone then underwent an 
intramolecular cyclization reaction leaving a free amine on the surface (2s) and releasing 
a lactone species (2l).  This amine terminus allows for a variety of subsequent reactions, 
including amide coupling chemistry, which is commonly utilized to attach biomolecules 
to surfaces.  We first illustrated the use of this electrochemical reduction process to attach 
ferrocene carboxylic acid to the surface, to form 3s, via amide coupling chemistry.  
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Scheme 1.4 The chemical and electrochemical steps involved in non-oxidatively 
activating Si(111) surfaces.  The molecules or molecular components are colored to 
highlight their different functions.  1s represents the surface-bound benzoquinone that 
resulted from the click reaction of 1 to the acetylene-modified Si(111) surface (reacted 
acetylene group drawn in black).  Upon reduction at –800 mV (vs Ag/AgCl) of the 
benzoquinone to the hydroquinone, an intramolecular cyclization reaction ensues to 
produce 2l (red lactone leaving group) and 2s (the green triazole ring with an amine 
terminus).  This represents the activated surface.  The ferrocene carboxylic acid (orange), 
a second electrochemically active molecule, is then coupled to the Si(111) surface. 
 
Ferrocene carboxylic acid (0.02 M) and N,N′-diisopropylcarbodiimide (DIC) (0.13 M) in 
DMF were added to the free amine surface.  The amide coupling reaction was run 
overnight covered in an N2-purged glove box.  The surface was then sonicated three 
times in DMF, then MeOH, and then blown dry. 
Biotin.  Biotin (0.02 M) and DIC (0.13 M) in DMF were added to the free amine surface 
2s.  The amide coupling reaction was run overnight in an N2-purged glove box at 50 °C.  
The surface was then sonicated three times in DMF, then MeOH, and blown dry.  
Subsequently, the Nanogold streptavidin (10 pM in 0.05% Tween20/DPBS) was 
introduced for 15 min.  The surface was sonicated in 0.05% Tween20/DPBS for 25 min 
and then water for 5 min.  The gold particles were then amplified with gold enhancement 
reagents for 10 min and then sonicated in water for 5 min. 
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1.3 Surface Characterization Methods 
1.3.1 X-Ray Photoelectron Spectroscopy  
X-ray photoelectron spectroscopy (XPS) was utilized to characterize many of the 
steps of both Schemes 1.2 and 1.4.  All XPS measurements were performed in an ultra-
high vacuum chamber of an M-probe surface spectrometer that has been previously 
described.54 All measurements were taken on the center of the sample at room 
temperature.  Monochromatic Al Kα X-rays (1486.6 eV) were incident at 35° from the 
sample surface and were used to excite electrons from samples.  The emitted electrons 
were collected by a hemispherical analyzer at a take-off angle of 35° from the plane of 
the sample surface. 
ESCA-2000 software was used to collect and analyze the data.  To get an 
overview of the species present in the sample, survey scans were run from 0 to 1000 
binding eV (BeV).  The Si 2p (97–106 BeV), Cl 2p (196–206 BeV), C 1s (282–292 
BeV), N 1s (393–407 BeV), Fe 2p (695–745 BeV), and Au 4f (77–97 BeV) regions were 
investigated in detail. 
1.3.2 Contact Angle Measurements 
The sessile contact angle of water on the functionalized Si(111) surface was used 
to check the fidelity of the monolayer for all surfaces of Schemes 1.2 and 1.4 except H- 
and Cl-terminated Si(111).  Contact angle measurements were obtained with an NRL 
C.A. Goniometer Model #100-00 (Rame-Hart, Inc.) at room temperature.  Contact 
angles, θ, were measured from sessile drops by lowering a 1 µl drop from a syringe 
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needle onto the surface.  This was repeated three times and averaged to obtain the θ for 
the surface. 
1.3.3 Electrochemical Characterization of Surface Coverages 
 Electrochemistry was performed in a custom-made cell using a VMP Multi-
Potentiostat (Princeton Applied Research, Oak Ridge, TN).  Dulbecco’s Phosphate 
Buffered Saline (DPBS) was used as the electrolyte, with silicon as a working electrode, 
a Pt coil as a counter electrode, and an Ag/AgCl reference electrode.  Molecular coverage 
was obtained by integrating the cathodic peak of the first scan in which all the modified 
benzoquinone was reduced to hydroquinone. 
1.3.4 Infrared Surface Characterization     
The H- and H-C≡C-terminated Si(111) surfaces were characterized by Attenuated 
Total Reflection Fourier Transform Infrared Spectroscopy (ATR-FTIR).  The Si(111) 
surfaces were prepared from single-crystal, polished Si(111), miscut 3–4°, boron-doped 
(n-type), 500–550 µm thick, and with 4–20 Ω-cm resistivity (Addison Engineering, Inc., 
San Jose, CA).  Samples were cut into (2 cm × 2 cm) pieces and underwent the 
acetylenylation and click reactions as described above.  Samples were mounted on a 
Germanium ATR crystal (GATR, Harrick Scientific Products, Inc.) for a grazing angle of 
65°.  The sample was placed in a Vertex 70 FT-IR spectrometer (Bruker Optics Inc.) for 
measurements.  In an air-purged sample chamber, 512 or 1024 scans were taken, with 
background scans of air subtracted from the spectra.  Spectra were fitted with a linear 
baseline prior to analysis. 
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1.4 Results and Discussions 
1.4.1 X-Ray Photoelectron Spectroscopy Measurements 
XPS survey scans revealed the progression of the acetylenylation and click 
chemistry steps.  For a freshly prepared, H-terminated Si(111) surface (H-[Si(111)]), Si 
2p and Si 2s peaks were observed, at 100 BeV and 150 BeV, respectively.  Additional 
small C ls and O ls peaks, corresponding to adventitiously adsorbed carbon and oxygen 
on the surface, were also detected.  After chlorination of H-[Si(111)] by PCl5, two new 
peaks at 200 BeV and 270 BeV appeared in the XPS spectrum, representing the Cl 2p 
and Cl 2s electrons, respectively.  Upon a treatment with sodium acetylide, the chlorine 
peaks disappeared and a pronounced C 1s appeared at 285 BeV, verifying that the 
acetylene-terminated Si(111) surface (H-C≡C-[Si(111)]) has been generated.  Other 
adsorbed carbon can contribute to the C 1s peak intensity for this scan.  After the click 
reaction, a new N 1s peak appears at 400 BeV. 
High-Resolution XPS Measurements.  High-resolution XPS measurements were 
utilized to quantitate the chemical steps of Schemes 1.2 and 1.4.  In particular, the Si 2p 
region was used to monitor the growth of silicon oxides as a function of exposure time to 
air (Figure 1.1) and as a function of the chemical and electrochemical steps of Scheme 
1.4 (Figure 1.2A) in two sets of experiments.  For both measurements, a Shirley baseline 
was applied to each spectrum before the peaks were fitted.  Peak line shapes for bulk Si  
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Figure 1.1 XPS data of H-C≡C-
[Si(111)], collected in the Si 2p region, 
and taken after exposure to air for up to 
160 hours.  The peaks for SiOx species 
should appear between 100 and 104 
BeV.  The amount of oxidation of the 
Si(111) can be estimated from this data 
to be < 0.25 equivalent monolayers.  
The Si 2p features are normalized to the 
same height for all three scans. The 37, 
79, 160 hours scans are shown offset 
from the 0 hours scan to reveal the 
spectral detail. 
2p3/2 and 2p1/2 were fitted to Voigt 
functions fixed at 95% Gaussian and 5% 
Lorentzian, with a 15% asymmetry.  The Si 
2p1/2 and 2p3/2 peaks were fitted with the 
two peaks held 0.6 BeV apart, the full 
width at half maximum (FWHM) was 
fixed at 1, and the integrated area ratio of 
the 2p1/2/2p3/2 peaks was fixed at 0.51, as 
has been previously described.30–32,40  The 
broad peak between 100 and 104 BeV was 
assigned as Si+ to Si4+ oxides and was 
fitted to a third peak.  The positions of the 
three peaks and the width of the third peak 
were optimized to get the best fit to the 
experimental spectrum.  For very thin oxide layers, the oxide coverage was calculated 
from the SiOx:Si 2p peak area ratio.  This was determined by dividing the area under the 
third peak by the total area of the Si 2p3/2 and 2p1/2 peaks.32 The SiOx:Si 2p peak area 
ratio was then divided by a normalization constant of 0.21 for Si(111) to estimate the 
fraction of surface atoms that were oxidized.30–32 We estimated that there were < 0.25 
equivalent monolayers of oxide on the acetylene-terminated Si(111) surface after 6 days 
exposure to air (Figure 1.1).  This is consistent with other results that have shown 
stability towards oxidation for as long as 60 days in air.40 Following the formation of 1s 
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and the reduction of 1s to 2s at –800 mV (Scheme 1.4), the amount of oxide was 
calculated to be 0.29 and 0.34 equivalent monolayers, respectively (Figure 1.2A). 
 
Figure 1.2 High-resolution XPS spectra of H-C≡C-[Si(111)], and of that surface 
following the click reaction to form 1s and the reduction of 1s to 2s.  A) Si 2p region 
revealing the near absence of oxide growth during the CuI-catalyzed click reaction, and 
during the reductive transformation of 1s to 2s.  B) Scan of the C 1s region of H-C≡C-
[Si(111)].  The Si-C peak is unique to H-C≡C-[Si(111)] surfaces.  The C-C peak contains 
contributions from the C≡C bond and adventitious carbon from the environment.  The C-
O peak present also arises from adventitious hydrocarbons.  C) Scan of the N 1s region of 
1s, validating the click formation of 1s.  The area ratio of the three peaks is 1:2:1, 
respectively.  D) Scan of the Fe 2p region showing the formation of 3s via the amide 
coupling of ferrocene carboxylic acid to 2s.  The control plots are of 1s (dark grey) and 
the H-C≡C-Si(111) surface (light grey) after exposure to ferrocene carboxylic acid under 
the same conditions.  
 
The H-C≡C-[Si(111)] surface was also characterized using high-resolution XPS 
of the C 1s spectrum (Figure 1.2B).  This spectrum was deconvoluted and fitted to three 
peaks, the silicon-bonded carbon at 283.8 BeV, the carbon-bonded carbon at 284.9 BeV, 
and the oxygen-bonded carbon at 286.8 BeV.  As developed by Nemanick,39,40 peaks 
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were fitted to Voigt functions having 70% Gaussian and 30% Lorentzian line shapes.  
The peak center-to-center distances were fixed at 1.1 BeV between the Si-C and C-C 
peaks, and at 2.9 BeV between the Si-C and O-C peaks.  To calculate the surface 
coverage of the acetylene the integrated area under the silicon-bonded carbon peak was 
ratioed to the total integrated area of the Si 2p3/2 and 2p1/2 peaks and normalized with 
respect to scan time.  The ratio calculated was referenced to a methyl terminated Si(111) 
surface that was scanned under the same conditions.  The effective coverage of acetylene 
on the Si surface was 97 ± 5 %, consistent with other measurements of such surfaces.41 
The statistical uncertainty in this number is largely determined by the signal-to-noise 
ratio of the XPS data (~ 30:1). 
The high-resolution N 1s spectrum of 1s illustrates the attachment of the 
benzoquinone (1) via click chemistry (Figure 1.2C).  The spectrum was deconvoluted and 
fitted to three peaks, each composed of 80% Gaussian and 20% Lorentzian line shapes.56 
The three peaks correspond to the amide nitrogen at 401.7 BeV, the doubly bonded 
nitrogen atoms (in the triazole ring) at 400.3 BeV, and the singly bonded nitrogen (in the 
triazole ring) at 398.2 BeV, respectively.  The ratio of peak areas was found to be 1:2:1, 
consistent with the structure of 1s.  After electrochemical cleavage to 2s, the N 1s region 
remained unchanged. 
Figure 1.2D is a high-resolution scan of the Fe 2p region that demonstrates the 
attachment of ferrocene carboxylic acid onto 2s to form 3s.  The Fe 2p3/2 and 2p1/2 peaks 
occur at 711.3 and 724.8 BeV, respectively.  It is difficult to quantify the amount of iron 
from such data because the peak shape is highly asymmetric and hard to deconvolute 
with a single Gaussian/Lorentzian function due to the strong multiplet splitting.56 
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However, as discussed below, the surface coverage of 3s can be estimated from cyclic 
voltammetry measurements.  Figure 1.2D also shows two control experiments.  Although 
a trace amount of ferrocene residue is detected on the controls, this measurement does 
confirm that the large majority of ferrocene is the result of the covalent bond formation 
between carboxylic acid of the ferrocene and the free amine of 2s. 
1.4.2 Contact Angle Measurements 
As the functionalized Si (111) surface changes and becomes more hydrophilic, the 
contact angle of water decreases. These results are listed in Table 1.1. 
Table 1.1 Measured contact angles for various Si(111) surfaces 
Surfaces Contact Angle (°) 
H-C≡C-[Si(111)] 77 ± 2 
1s 68 ± 2 
2s 60 ± 2 
3s 59 ± 2 
 
1.4.3 Electrochemical Characterization of Surface Coverages 
Figure 1.3A depicts the cyclic voltammogram (CV) for 1s.  The prominent 
cathodic peak in the first scan confirms the presence of electroactive benzoquinone and, 
therefore, that the click reaction proceeded.  Molecular coverage was obtained by 
integrating the cathodic peak of the first scan in which all the modified benzoquinone was 
reduced to hydroquinone.  Complete conversion of 1s to 2s accompanied by the release 
of 2l (Scheme 1.4) was achieved at potentials below –0.9 V.  Consecutive CV scans show 
that no detectable benzoquinone remained.  For the determination of coverage, the area 
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under the cathodic peak was obtained after subtracting the non-Faradaic current.  This 
area was converted to the number of molecules by a stoichiometric ratio of 2 electrons to 
1 electroactive molecule.  Then the number of molecules was divided by the electrode 
surface area and then normalized to the Si atop atom surface density (7.8 × 1014 /cm2 for 
Si(111)).17 The coverage calculated for 1s on the H-C≡C-[Si(111)] was 6.7 ± 0.3 %.  
 
Figure 1.3 Cyclic voltammetry (CV) results for 1s and 3s.  A) The electrochemical 
activation of 1s   2s.  The black trace is of the first scan, and the grey traces are of two 
subsequent scans, indicating nearly complete conversion of benzoquinone to 
hydroquinone during the first scan.  B) The reversible oxidation of 3s.  Two subsequent 
scans are shown.  All voltages are relative to Ag/AgCl. 
 
Figure 1.3B represents a CV of 3s, the product of the amide coupling of ferrocene 
carboxylic acid with 2s.  The CV shows reversible Fc0/+ redox behavior, as expected for 
ferrocene oxidation.  The peak spacing confirms that ferrocene is covalently attached (but 
not adsorbed) onto the surface. The coverage was calculated by integrating the anodic 
peak after subtracting the non-Faradaic current.  The number of molecules was divided 
by the electrode surface area and normalized to Si atom surface density which is 7.8 × 
1014 /cm2 for Si(111).17  The coverage calculated for 3s was 0.5%. 
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1.4.4 Surface Coverages Summary 
The coverage values for H-C≡C-[Si(111)], surface 1s, and surface 3s are 
summarized in Table 1.2, calculated with respect to all atop sites on an unreconstructed 
Si(111) surface. 
Table 1.2 The measured molecular surface coverages for various Si(111) surfaces, as 
measured by XPS or electrochemistry (EC) 
Surfaces Coverage (%) 
H-C≡C-[Si(111)] 97 ± 5 (XPS) 
1s - benzoquinone 6.7 ± 0.3 (EC) 
3s - ferrocene 0.5 (EC) 
 
The 97% coverage of the H-C≡C-[Si(111)] surface is consistent with the Si 2p 
XPS in Figure 1.1 (and other studies41) that indicated little surface-bound SiOx.  The 
acetylene carbons are sp-hybridized, implying a perpendicular attachment to the Si(111) 
surface.  The atomic radius for C is smaller than that for Si (0.70 Å vs 1.10 Å), and there 
is a 3.8 Å spacing between atop sites on Si(111).  These values support the notion that a 
100% passivation of Si(111) surfaces can be achieved using the approach we described 
here. 
The coverage of the electroactive benzoquinone 1 on Si(111) to form 1s was 
calculated to be ~ 7% of all available Si(111) atop sites.  We previously reported on 
electrochemically activating Si(111) and Si(100) surfaces through the use of protected 
hydroquinones that were attached to H-terminated Si surfaces via UV activation.17  For 
those molecules, coverages of up to 23% were achievable on Si(111), although bulkier 
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protection groups on the hydroquinone led to slightly reduced surface coverages, 
implying steric interactions played at least some role in limiting coverage.  It is likely that 
steric interactions play a dominating role in determining the efficiency of the click 
reaction to form 1s.  While the acetylene footprint may be approximated by the van der 
Waals radius of the carbon atom, the triazole ring formed upon the click reaction will 
obviously be much larger.  In fact, it is possible that the click chemistry is only effective 
at the step edges of the Si(111) surface.  We have extensively characterized various 
Si(111) surfaces that have been alkylated using the two-step chlorination/alkylation 
chemistry using high-resolution Scanning Tunneling Microscopy (STM).  For both 
methylated31,36 and ethylated37 Si(111), we find that about 10% of the Si surface atoms lie 
at step edges.  This arises from etch pits that are apparently formed during the 
chlorination step57, implying that the H-C≡C-[Si(111)] surface likely has a similar 
morphology.  In that case, acetylene groups located at step edges would not have the 
steric constraints that would limit the formation of the triazole ring.  It is interesting that 
the 7% coverage of 2s is similar to the number of Si atop sites that would reside at step 
edges. 
1.4.5 Infrared Surface Characterization     
Additional support for 100% acetylenylation of Si(111) comes from the ATR-
FTIR measurements of H-[Si(111)] and H-C≡C-[Si(111)] (Figure 1.4; black and grey 
traces, respectively).   
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Figure 1.4 ATR-FTIR characterization of a H-[Si(111)] and of H-C≡C-[Si(111)] in the 
region of the 2083 cm-1 Si-H mode 
 
Whereas XPS allows analysis of the elemental composition of surfaces, infrared 
spectroscopy (IR) gives information about the types of chemical functionality on a 
surface.  The spectra shown in Figure 1.4 are expanded to highlight the region containing 
the signature Si-H (2083 cm-1) stretching frequency that is observed for the H-[Si(111)].  
The Si-H stretch is strong and sharp, indicating that the surface sites are passivated with 
one hydrogen atom per atop site.  This is expected for a H-[Si(111)] freshly prepared by 
an NH4F(aq) etch.58  For H-C≡C-[Si(111)], the 2083 cm-1 vibration has quantitatively 
disappeared, again consistent with 100% acetylenylation and with other work.41  A weak 
C≡C stretch might be expected in this region (2120–2175 cm-1),41,47 although we have not 
observed it.  When H-[Si(111)] is ethylated through a similar chlorination/alkylation 
procedure, the coverage of ethyl groups on the atop sites of the Si(111) surface is limited 
by steric interactions to be approximately 80%.37  Following the Grignard alkylation of 
Si(111), no Cl is detected on the surface,30 and FTIR data indicates that the remaining 
Si(111) atop sites are hydrogenated.59  For the ethylated surface, the 2083 cm-1 feature is 
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broadened, shifted (to 2070 cm-1), and reduced in intensity to 14% of that observed for 
the H-[Si(111)] surface.59 
1.4.6 Biofunctionalization of Si(111) Surfaces 
The stated goal of this work was to develop a general strategy for 
electrochemically directing the biofunctionalization of Si(111) surfaces without oxidizing 
the underlying Si(111).  To this end, we demonstrated the electrochemical activation and 
subsequent attachment of the model biomolecule, biotin, using a modification of the 
chemistry described in Scheme 1.4.  
 
Figure 1.5 Demonstration of bioattachment to H-C≡C-[Si(111)], through reductive 
formation of 2s followed by the amide coupling of biotin. A) XPS of the biotinylated 
Si(111) surface following exposure to strept-Au, but before Au amplification. The three 
SEM images (B, C, and D) are of the activated and biofunctionalized surface, plus two 
controls. All images were taken following the electroless amplification step. The scale 
bar is 1 µm.  B) 2s, incubated with biotin, and exposed to strept-Au. C) H-C≡C-[Si(111)] 
incubated with biotin, and exposed to strept-Au. D) 1s incubated with biotin, and exposed 
to strept-Au. There are at least 500 Au nucleation sites on B, 5 on C, and 7 on D.  
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Figure 1.5A shows the XPS of the biotinylated Si(111) surface following exposure to 
strept-Au, but prior to the electroless Au amplification. The Au 4f region is comprised of 
two spin-orbit coupled peaks: Au 4f7/2 (~ 84 BeV) and Au 4f5/2 (~ 88 BeV). The dotted 
trace is from H-C≡C-[Si(111)], and the gray trace is from 1s, each exposed to biotin and 
strept-Au as controls.  To detect surface-bound biotin, we utilized Au nanoparticle-
labeled streptavidin (strept-Au) and followed through with electroless amplification of 
the Au to produce particles that were imaged using Scanning Electron Microscopy 
(SEM).  Representative data from this experiment, shown in Figure 1.5B, indicates that 
the selectivity for attachment of strept-Au onto 2s is about 100-fold greater than on two 
control surfaces, H-C≡C-[Si(111)] and 1s, both of which were also treated with biotin 
and exposed to strept-Au. 
1.5 Conclusion 
Acetylenylation of the Si(111) surface via the two-step chlorination/alkylation 
procedure was combined with click chemistry to provide a non-oxidative approach for 
adding chemical functionality to a silicon surface.  Si(111) surfaces can be nearly 100% 
passivated with acetylene groups.  A specifically designed, electroactive benzoquinone 
molecule has been immobilized to the H-C≡C-[Si(111)] surface.  A 7% coverage of the 
benzoquinone was found, which implies that the click reaction likely occurred at step 
edges on the H-C≡C-[Si(111)] surface.  The attachment of an electroactive benzoquinone 
was highly selective and was accomplished with only a minimal amount of oxidation of 
the underlying Si(111).  The electroactive benzoquinone was reduced and cleaved from 
the surface to produce an amine terminus.  In separate experiments, ferrocene carboxylic 
acid and biotin were selectively and covalently immobilized to the electrochemically 
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activated surface. X-ray photoelectron spectroscopy (XPS), Fourier transform infrared 
spectroscopy (FTIR), cyclic voltammetry (CV), and contact angle goniometry were 
utilized to characterize and quantitate each step in the functionalization process.  As a 
result, the actylene and click chemistries can modify silicon surfaces with minimal 
oxidation.  This approach can be used as a general platform to prepare functional surfaces 
for various applications and can be extended towards the selective biopassivation of 
capture agents to nanoelectronic sensor devices. 
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2.1 Introduction 
In vitro diagnostic tests can be instrumental in the characterization of disease 
pathways and mechanisms of cancer, providing more-targeted treatment plans and better 
survival rates for patients.  Quantitative, multi-parameter measurements of proteins in the 
blood, which monitor the changes in protein levels in a patient, will revolutionize in vitro 
diagnostics.  A major challenge in realizing this goal is to find an efficient and general 
approach for producing protein capture agents for protein-biomarker-based detection that 
have positive attributes of antibodies, and exhibit a high level of chemical and 
biochemical stability.  Antibodies are proteins and are, thus, unstable towards thermal 
shock, dehydration, pH variation, degradation and many chemical processes.  In addition, 
developing a high affinity and selectivity antibody is very expensive and time consuming.  
Therefore, commercial antibodies do not exist for all proteins.1 This is becoming an 
increasingly important problem as diagnostic measurements of proteins are quickly 
moving from single parameter to multi-parameter assays of large panels of biomarkers.2–4 
Despite the drawbacks, antibodies remain the standard protein capture agent used in 
protein assays because of their high sensitivity and selectivity for their cognate proteins. 
Nucleic acid aptamers, small molecules, and phage-display peptides are 
alternatives to antibodies.  Nucleic acid aptamers5–7 are promising alternatives, with an 
extensive sequence space that can be screened in parallel (~ 1015 elements).8  However, 
the chemical diversity of aptamers is typically limited to 4 chemical constituents rather 
than 20 amino acids compared to peptides. Although, aptamers have been prepared as 
protein capture agents (KD ≈ 10-8-10-9 M), the synthetic scale-up can be nontrivial as 
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aptamers are large (5–25 kDa) oligomers.9 Also, aptamer length does not directly 
translate to high three-dimensional diversity.10 
Small molecule inhibitors, while displaying very high-affinity binding (KD ≈ 10-8–
10-13 M), bind to just one epitope on the protein of interest, and that epitope may not be 
unique to the single protein against which the inhibitor is developed.  This means that the 
inhibitor may exhibit cross-reactivity with other related proteins.11 Moreover, small 
molecule libraries can be time-consuming to synthesize, and such libraries do not 
represent a generic platform for screening against all proteins.  
Peptides selected by phage display methods also can offer reasonably high-
affinity binding (KD ≈ 10-8–10-9 M) to a protein target with a relatively low molecular 
mass.4,12  However, for phage display approaches, peptides are limited to linear 
sequences comprised of naturally occurring L-amino acids that provide poor 
bioavailability and enzymatic degradation.  Other characteristics, such as water solubility, 
are inconsistent and dependent upon the amino acid composition of the peptide. 
Peptide affinity agents can also be identified using one-bead one-compound 
(OBOC) libraries.13–15 This approach allows for the inclusion of broad classes of amino 
acids, including artificial and nonnatural amino acids,16,17 peptoids,18 and other 
peptidomimetics.19  However, serious trade-offs between peptide length and library 
diversity have to be made, since OBOC libraries are typically only 104–106 elements in 
size.  Phage display, by contrast, produces ~ 1012 element libraries.  As a result, high 
quality protein capture agents are rarely identified from OBOC peptide libraries.  
In situ click chemistry,20–23 as a target-guided24–26 approach, has been utilized 
previously for the identification of small molecule enzymatic inhibitors.  For this method, 
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the protein target replaces the role of a Cu(I) catalyst for promoting the 1,3-dipolar ‘click’ 
cycloaddition reaction between two low-affinity molecules into a single high-affinity 
bivalent ligand or biligand.  In these studies, a known small molecule inhibitor to a 
biological target is divided into parts, each part is expanded into a small library and 
engineered to have a terminal alkyne or azide functionality.  The uncatalyzed click 
reaction, which is slow at room temperature, is accelerated when the azide and alkyne 
groups are held within close proximity by the biological target (for example, a protein).  
Under this condition, the azide and alkyne ‘click’ together irreversibly, creating a bivalent 
enzymatic inhibitor.  This approach has been used to assemble small molecule inhibitors 
to aceytlcholinesterase (AChE), carbonic anhydrase (CA), and HIV-1 protease with sub-
pM binding affinities,20–26 and we have shown that peptide-based high-affinity lead 
compounds can be isolated with similar success. Furthermore, when a molecule with a 
10-4-M affinity is combined with a molecule with a 10-9-M affinity, the ‘clicked’ product 
can exhibit an affinity as high as 10-13 M (Figure 2.1).21 While achieving the full product 
affinity may be rare, increasing the affinity by 2 to 3 orders of magnitude per additional 
ligand should be readily achievable. 
 
Figure 2.1 In situ click chemistry schematic.  Azide-alkyne partners (represented by the 
green hemisphere and blue cylinder, respectively) can click together on bovine carbonic 
anhydrase II (bCAII).  The expected affinity for the biligand could approach 1 x 10-14 M. 
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If the achieved affinity and selectivity of the biligand is not sufficient for the desired task, 
then the biligand itself may be treated as an anchor ligand, and the in situ click chemistry 
process may be repeated as needed to prepare triligands.27,28   This process can further be 
repeated to produce multi-ligands, such as tetraligands, pentaligands, etc., until the 
desired affinity is achieved.  Thus, multi-valent binding agents can provide a potential 
shortcut to high affinity.29 This approach is used here as a general platform for high-
throughput peptide capture agent development.  
We have generalized the in situ click chemistry strategy for producing protein 
capture agents by implementing peptides selected from OBOC libraries.13–15  
 
Scheme 2.1 Identifying a protein capture agent via in situ click screen 
 
OBOC libraries allow thousands to millions of compounds to be rapidly prepared on bead 
and screened concurrently for specific binding.  For many biological targets, recognition 
of targets is effective using peptides as small as three-to-five amino acids in length.30,31 
Therefore, penta- to heptapeptide libraries were expected to afford enough diversity to 
discriminate between weak and strong binders.  OBOC libraries offer a distinct advantage 
in which nonnatural modifications are easily accomplished, allowing for incorporation of 
almost infinite diversity elements.  Natural, nonnatural, and artificial amino acids are 
assembled together to form peptides using standard coupling chemistries.32 D-amino 
acids were chosen for the core of the library so that the synthesized peptides have an 
  Zn…Z2Z1 
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increased resistance to enzymatic degradation when applied to in vivo assays.  Azide-
containing amino acids displaying 4-carbon (Az4) or 8-carbon (Az8) azidoalkyl linkers 
and D-propargylglycine (D-Pra) are chosen as the azide and alkyne handles, 
respectively, for click chemistry (Figure 2.2). Azides and alkynes are also chemically 
attractive because they are synthetically convenient to introduce, compatible with a 
variety of solvents and species, and tolerant of other functionalities.  The OBOC library 
technique also allows for desirable chemical and physical properties, such as water 
solubility, to be precisely tuned in the peptide capture agent.  Scalability to gram 
quantities can be done straightforwardly and significantly cheaper than with antibodies.   
N
OH
N3
O
H
Fmoc
n
N
OH
O
H
Fmoc
D-PraAz4 (n=4)
Az8 (n=8)  
Figure 2.2 Azide- and acetylene-containing amino acids used in this study 
 
Herein, I describe the use of in situ click chemistry as a general synthetic 
approach towards identifying high-quality, inexpensive protein capture agents.  This 
chapter covers the synthesis of the azide-containing artificial amino acids, peptide library 
construction, on bead click reaction, and bead-based library screening procedures. Edman 
sequencing of lead compounds, including the custom gradient that was designed to allow 
for elution and verification of the artificial amino acids are also described in this section.  
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2.2 Artificial Amino Acid Synthesis  
Azide-containing amino acids were synthesized and characterized, and used as 
handles for click chemistry following Scheme 2.2.   
 
Scheme 2.2 Synthesis for azide-containing artificial amino acids 
 
Azidobutylbromide (1a).  To a solution of 1,4-dibromobutane (123 mmol) in N-
N'-dimethylformamide (DMF), sodium azide (61.5 mmol) was added and stirred 
overnight at 50 °C. The reaction was diluted with ethyl acetate, and the organic layer was 
washed with water, then brine, and dried over MgSO4.  The crude residue was purified by 
silica gel chromatography (100% hexanes) to give a product (80%) as a clear oil.  1H 
NMR (300 MHz, CDCl3): δ 3.44 (2H, t, J = 6.3 Hz), 3.34 (2H, t, J = 6.6 Hz), 1.93–1.98 
(2H, m), 1.74–1.79 (2H, m). 
Azidooctylbromide (1b).  Synthesis was carried out as described above, except 
1,8-dibromobutane was used as the starting material.  1H NMR (300 MHz, CDCl3): δ 
3.41 (2H, t, J = 6.9 Hz), 3.26 (2H, t, J = 6.6 Hz), 1.86 (2H, p, J = 6.9 Hz), 1.60 (2H, p, J 
= 8.7 Hz), 1.34–1.55 (4H, m). 
Diethyl 2-acetamido-2-(4-azidobutyl)malonate (2a).  To a solution of 0.598 g 
(0.026 mol) sodium metal in 25 mL absolute EtOH, 5.65 g diethyl acetamidomalonate 
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(0.026 mol) was added, following previously published procedures.33 The mixture was 
stirred for 30 min at room temperature.  By dropwise addition, azidobutylbromide 1a 
(4.82 g, 0.027 mol) was added with stirring.  The reaction mixture was stirred for 2 hours 
at room temperature and refluxed for 6 hours at 80 °C.  After cooling overnight, the 
reaction mixture was concentrated to dryness, and the residue was extracted with diethyl 
ether.  The combined ether extracts were washed with water, sat. NaHCO3, water, and 
brine, and were dried over MgSO4 and then concentrated.  Silica gel chromatography 
(Hex:EtOAc = 1:1) gave a product (63%) as a clear, viscous oil.  1H NMR (300 MHz, 
CDCl3): δ 6.77 (1H, s), 4.24 (4H, q, J = 6.9 Hz), 3.26 (2H, t, J = 6.9 Hz), 2.31–2.37 (2H, 
m), 2.04 (3H, s), 1.59 (2H, p, J = 7.5 Hz), 1.26 (6H, t, J = 6 Hz), 1.16–1.27 (2H, m).  
ESI-MS m/e 315. 
Diethyl 2-acetamido-2-(4-azidooctyl)malonate (2b).  Similar synthetic protocol 
as 2a was adopted, only azidooctylbromide 1b served as the starting material.  1H NMR 
(300 MHz, CD3Cl3): δ 6.76 (1H, s), 4.24 (4H, q, J = 7.2 Hz), 3.24 (2H, t, J = 6.9 Hz), 
2.27–2.33 (2H, m), 2.04 (3H, s), 1.56 (2H, p, J = 7.5 Hz), 1.25 (6H, t, J = 7.2 Hz), 1.06–
1.16, 1.2–1.4 (10H, m).  ESI-MS m/e 371. 
2-Azidobutyl amino acid (3a).  Following standard methods34, the diester 2a (2.8 
mmol) in 25 mL of 10% NaOH solution was heated to reflux for 4 hours.  The solution 
was then neutralized with concentrated HCl and evaporated.  The residue was dissolved 
in 25 mL of 1 M HCl and heated to reflux for 3 hours.  The solvent was reduced and 
extraction with MeOH which afforded amino acid 3a as the hydrochloride salt (85%).  1H 
NMR (300 MHz, CD3OD): δ 3.98 (1H, t, J = 6.3 Hz), 3.35 (2H, t, J = 7.8 Hz), 1.45–1.7, 
1.85–2.05 (6H, m).  MALDI-MS m/e 173. 
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2-Azidooctyl amino acid (3b).  Synthesis was carried out as described above, 
using diester 2b as the starting material.  1H NMR (300 MHz, CD3OD): δ 3.94 (1H, t, J = 
6.3 Hz), 3.27 (2H, t, J = 6.9 Hz), 1.3–1.52, 1.52–1.62, 1.8–1.98 (14H, m).  ESI-MS m/e 
229. 
Fmoc-2-Azidobutyl amino acid (Fmoc-Az4-OH).  The amino acid 3a (26.3 
mmol) was dissolved in 0.45:0.55 H2O:THF (150 mL), and NaHCO3 (22.1 g, 263 mmol) 
was added, following published methods.35  After the mixture was cooled to 0 °C, Fmoc-
OSu (9.7 g, 28.9 mmol) was added dropwise over 5 min.  The reaction mixture was 
allowed to come to room temperature and stirred overnight.  Evaporation of THF was 
completed in vacuo and the aqueous residue was washed with diethyl ether (2 × 200 mL).  
The aqueous layer was then collected and acidified with conc. HCl to pH 2 before 
extraction with ethyl acetate (4 × 100 mL).  The combined organic layers were washed 
with brine, dried over MgSO4, filtered, and concentrated.  The organic residue was 
purified by column chromatography (2% MeOH in DCM) to yield a white powder (48% 
yield).  1H NMR (300 MHz, CDCl3): δ 7.76 (2H, d, J = 7.5 Hz), 7.59 (2H, d, J = 6.9 Hz), 
7.40 (2H, t, J = 7.5 Hz), 7.31 (2H, t, J = 7.5 Hz), 5.34 (1H, d, J = 7.8 Hz), 4.49–4.59 (1H, 
m), 4.43 (2H, d, J = 6.6 Hz), 4.22 (1H, t, J = 6.6 Hz), 3.27 (2H, t, J = 6.6 Hz), 1.3–2.0 
(6H, m).  ESI-MS m/e 395. 
Fmoc-2-Azidooctyl amino acid (Fmoc-Az8-OH).  The amino acid 3b was 
treated to Fmoc protection as described above.  1H NMR (300 MHz, CD3Cl3): δ 7.75 (2H, 
d, J = 7.5 Hz), 7.57–7.61 (2H, m), 7.39 (2H, t, J = 7.5 Hz), 7.30 (2H, t, J = 7.2 Hz), 5.40 
(1H, d, J = 8.1 Hz), 4.42–4.52 (1H, m), 4.40 (2H, d, J = 7.2 Hz), 4.21 (1H, t, J = 7.2 Hz), 
3.23 (2H, t, J = 6.9 Hz), 1.18–1.98 (14H, m).  ESI-MS m/e 450. 
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2.3 One-Bead One-Compound Peptide Library Construction 
2.3.1 Materials.  Fmoc-D-X-OH (Fmoc, fluoren-9-ylmethoxycarbonyl) (X = Ala, 
Arg(Pbf) (Pbf, pentamethyldihydrobenzofuran-5-sulfonyl), Asn(Trt) (Trt, trityl), 
Asp(OtBu) (tBu, tert-butyl), Glu(OtBu), Gln(Trt), Gly, His(Trt), Ile, Leu, Lys(Boc) 
(Boc, tert-butyloxycarbonyl), Met, Phe, Pro, Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu), 
and Val) were purchased (Anaspec; San Jose, CA). TentaGel S-NH2 resin (90 µm, 0.31 
mmol/g) (Rapp-Polymere; Tübingen, Germany) were utilized for OBOC library 
construction. Amino acid coupling reactions were performed in 1-methyl-2-pyrrolidinone 
(NMP, 99%) with HATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylammonium hexafluorophosphate, ChemPep; Miami, FL) and N,N′- 
diisopropylethylamine (DIEA). For removal of Nα-Fmoc protecting groups, a solution of 
20% piperidine in NMP was used. For final deprotection of the peptide libraries, 
trifluoroacetic acid (TFA, 98% min. titration) and triethylsilane (TES) were used. All 
solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
OBOC libraries were synthesized using a 180-degree variable-speed shaker, fitted 
with small sample adapter (St. John Associates; Beltsville, MD). Fritted polypropylene 
solid-phase synthesis tubes were used for repeated split-mix cycles. A 24-port SPE 
vacuum manifold system (Grace, Deerfield, IL) was used for exchanging coupling 
solutions and washing the resins. Fmoc-D-propargylglycine (Fmoc-D-Pra-OH) was 
acquired (Chem-Impex International; Wood Dale, IL) and used as the acetylene handle for 
construction of ligands. 
Fmoc-D-propargylglycine (Fmoc-D-Pra-OH) was acquired (Chem-Impex 
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International; Wood Dale, IL) and used as the acetylene handle for construction of ligands.   
2.3.2 Library Construction.  Randomized OBOC libraries of penta- to 
heptapeptides were synthesized manually via standard split-and-mix solid-phase peptide 
synthesis methods on 90 µm polyethylene glycol-grafted polystyrene beads (TentaGel S-
NH2, 0.31 mmol –NH2/g, 2.86 x 106 beads/g, Rapp Polymere, Tübingen, Germany)13–15.  
Each bead is functionalized with a unique chemical entity (Figure 2.3).  At least a five 
fold excess of beads was utilized in each library synthesis to ensure adequate 
representation of each library element.  Nonnatural D-stereoisomers (denoted by 
lowercase one-letter amino acid code) were used at every possible position in the peptide 
sequence (See Appendix A for the structure of the D-amino acids).  Acetylene and azide-
containing amino acids are coupled to the N- and C-termini to serve as handles for click 
chemistry.  The distance between the azide and alkyne during the in situ click experiment 
cannot be predicted in advance, so the incorporation of the variable length azidoalkyl 
linker may improve the assembly of the click product on the face of the protein.  
 
Figure 2.3 Solid-phase mix-and-split combinatorial synthesis 
A standard solid-phase peptide synthesis method with 9-fluorenylmethoxycarbonyl 
(Fmoc) chemistry was used.36 All wash, deprotection, and coupling steps were facilitated 
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by 180-degree shaking of the resin.  The resin was pre-swelled in N-methylpyrrolidinone 
(NMP) in a plastic disposable reaction vessel with fritted ends.  The resin was separated 
into multiple aliquots and each aliquot was reacted with two fold molar excess (relative to 
resin) of a single Nα-Fmoc-amino acid.  Amide coupling was initiated by addition of a 
two fold molar excess of HATU and a six fold molar excess of N,N′-
diisopropylethylamine (DIEA). The coupling reaction was run for 15 min.  Another 2 
equiv Nα-Fmoc-amino acid, 2 equiv HATU, and 6 equiv DIEA were added, and allowed 
to react for 15 min (“double coupling”).  In some cases, “triple coupling” with a third set 
of coupling reagents and Nα-Fmoc-amino acid was performed (Table 3.1, Libraries D, E, 
F, and G).   
After coupling, the aliquots are thoroughly washed (5 x NMP), mixed together 
into a single vessel, and deprotected with 20% piperidine in NMP (30 min).  The resins 
are thoroughly washed again (5 x NMP), dried (5 x DCM), and redivided into multiple 
aliquots for the next cycle of coupling.  This second cycle of coupling adds another single 
Nα-Fmoc-amino acid to the growing peptide chain.  The procedures of couple, wash, mix, 
deprotect, and split iterate until the desired length of peptide is attained. 
The amino acid side-chain protecting groups are removed by incubation in 95% 
trifluoroacetic acid (TFA), 5% water, and triethylsilane (two fold molar excess per 
protected side chain) for 2 hours. The library resin was then neutralized with DMF, and 
washed thoroughly with DMF (5 x), water (5 x), methanol (MeOH, 5 x), and methylene 
chloride (DCM, 5 x)37 and then dried under vacuum and stored in phosphate-buffered 
saline [PBS (pH 7.4)] + 0.05% NaN3 at 25 °C. 
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2.4 On Bead Click Reaction 
2.4.1 Materials.  For peptide biligand and triligand synthesis, acetylation reagents 
(acetic anhydride, 2,6-lutidine, and N,N-dimethylformamide (DMF)) were purchased 
from Sigma-Aldrich (St. Louis, MO).  For the on bead Cu(I)-catalyzed click reaction, 
copper(I) iodide, L-ascorbic acid, and sodium diethyldithiocarbamate trihydrate were 
purchased from Sigma-Aldrich (St. Louis, MO). 
2.4.1 Click Reaction.  For preparing biligand and triligand candidates, the Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) on bead was completed in four general 
steps: (1) anchor ligand synthesis, (2) acetylation, (3) click reaction, and (4) addition of 
2° ligand sequence.  Scheme 2.3 illustrates these reactions (Z = any amino acid).   
 
Scheme 2.3 On bead ‘classic’ click reaction  
We found that the azide moiety needed to be attached to the bead and that the alkyne 
molecule needed to be in solution for the click reaction to work efficiently.  For the 
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acetylation, the fully protected TentaGel S-NH2 bead-bound anchor ligand (0.420 g, 0.13 
mmol) was capped by a solution of acetic anhydride (1 mmol) in DMF, containing a 
catalytic amount of 2,6-lutidine.38  
The acetylated peptide was reacted with Fmoc-D-Pra-OH (0.218 g, 0.65 mmol) in 
the presence of copper(I) iodide (0.124 g, 0.65 mmol), L-ascorbic acid (0.114 g, 0.65 
mmol), and DMF/piperidine (8/2) at 25 °C for 6 hours.39  The resin was washed with 5 × 
5 mL sodium diethyldithiocarbamate trihydrate (Et2NCSSNa•3H2O, 1% w/v), containing 
1% DIEA (v/v) in DMF to remove excess coordinated copper.40   Following the click 
reaction, the next Nα-Fmoc-amino acid was added to the peptide chain.   
 
2.5 Bead-Based Library Screening Procedures 
2.5.1 Proteins. Bovine carbonic anhydrase II (bCAII, C2522), from bovine 
erythrocytes, lyophilized powder, was obtained from Sigma-Aldrich (St. Louis, MO) and 
used as recieved.  To prepare the protein for screening, dye-labeling was accomplished 
with the Alexa Fluor 647 Microscale Protein Labeling Kit (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol for low degree of labeling (DOL).  Protein (100 
µg) was incubated with 6 mol equiv Alexa Fluor 647 succinimidyl ester for 15 min at 25 
°C.  Excess dye was removed by BioGel P-6 size exclusion resin (Bio-Rad, Hercules, 
CA).  The labeled protein (bCAII-Alexa647) was characterized by UV-Vis and mass 
spectrometry. 
2.5.2 Screening.  A typical peptide library screen against bCAII is described as 
follows.  The peptide library is screened not all at once, but in several mg portions.  
Approximately 10–20 mg dried peptide-bead library is incubation in PBS (pH 7.4) + 
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0.1% Tween 20 + 0.1% bovine serum albumin (BSA) + 0.05% NaN3 (PBSTBNaN3) for 1 
hour, with shaking, to block nospecific protein binding.41 The library was then washed 
with 3 x 5 mL PBSTBNaN3 only.  On bead multi-ligand screens were conducted at an 
appropriate bCAII-Alexa Fluor 647 dilution (Table 2.1), and then washed with 3 x 5 mL 
PBSTBNaN3, 3 x 5 mL PBS (pH 7.4) + 0.1% Tween 20, and finally 6 x 5 mL PBS (pH 
7.4). All in situ screens contained an additional 2 hours preincubation of bCAII-Alexa 
Fluor 647 with anchor ligand (≥ 2000 equiv, relative to protein), after which the bead 
library was added to this mixture and the screen was continued (Table 2.1).  Following in 
situ screening, beads were washed with 3 x 5 mL PBSTBNaN3, 3 x 5 mL PBS (pH 7.4) + 
0.1% Tween 20, and then 6 x 5 mL PBS (pH 7.4). We found that longer incubation times, 
up to 24 hours, select for more specific tight-binding events and promote dissociation of 
the weakly bound peptides. 
Table 2.1 Screening summary; pH=7.4 and T=25oC, unless otherwise noted  
Screen Library [bCAII-
AF647] 
Time(h)  % hit beads Buffer Other 
components 
An1 A 100 nM 1 h 0.02% PBS   
An2a B 50 nM 1 h 0.09% PBS   
An2b B 8 nM 24 h 2 hits PBS   
Bi1 C 50 nM 2 h; 37o (no 
beads) + 48 
h; 37o 
0.007% PBS + 1% 
DMSO (v/v) 
100 µM of lklwfk-
(D-Pra) 
Bi2a D 50 nM 17 h 0.07% PBSTBNaN3   
Bi2b D 10 nM 17 h 0.008% PBSTBNaN3   
Tri1 C 10 nM 2 h (no 0.007% PBSTBNaN3 + 100 µM of (D-
Pra)-kwlwGl-
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beads) +15 h 1% DMSO (v/v)   Tz1-kfwlkl 
Tri2 E 10 nM 17 h 0.008% PBSTBNaN3   
TriX A 10 nM 17 h 0.007% PBSTBNaN3 + 
1% DMSO (v/v)   
100 µM of (D-
Pra)-kwlwGl-
Tz1-kfwlkl 
Tri3 F 0.5 nM 2 h (no 
beads) +18 h 
0.005-0.01% PBSTBNaN3 + 
1% DMSO (v/v)   
100 µM of (D-
Pra)-kwlwGl-
Tz1-kfwlkl 
Tri4 G 0.25 nM 18 h 0.005-0.01% PBSTBNaN3   
 
Anchor ligand screens (An1, An2a, An2b) were conducted using Libraries A 
and B.  Following screening, the beads were washed with 3 x 5 mL PBS (pH 7.4), then 7 
x 5 mL water. 
In situ biligand and triligand screens were carried out utilizing Libraries C and F.  
On bead biligand and triligand screens were performed using Libraries D, E, and G.  
Screening conditions are provided in Table 2.1, and further details will follow. 
After incubation, the peptide-bead library and protein screening solution is 
transferred into a clean polyethylene-fritted vessel.  The beads are filtered in vacuo, then 
washed with 0.1% Tween20/PBS (3 x 1 ml) followed by PBS pH 7.4 (3 x 1 ml), followed 
by H2O (7 x 1 ml).  The washed peptide-bead library sample is transferred onto a glass 
microscope slide and immediately imaged using a GenePix 4200 array scanner (λex = 635 
nm).  These individual hit beads, which are white due to saturation of the PMT gain, are 
manually selected using a glass micropipette. 
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Figure 2.4 Imaging hit beads 
 
To remove bound proteins, each hit bead was incubated in 7.5 M guanidine 
hydrochloride (pH 2.0) for 1 hour, followed by ten rinses with water. These hits are 
considered lead compounds, and their sequences are analyzed by Edman degradation. 
 
2.6 Analysis of Lead Compounds by Edman Degradation 
2.6.1 Method.  Edman sequencing of single hit beads was carried out on a Model 
494 Procise cLC Sequencing System (Applied BioSystems, Foster City, CA). Edman 
sequencing requires that the peptide have a free N-terminus on α-amino acids for 
determination of a peptide’s sequence.  Edman degradation works in the following way: 
Phenylisothiocyanate (PITC) is reacted with an uncharged terminal amino group, under 
mildly alkaline conditions, to form a cyclic phenylthiocarbamoyl derivative. Then, under 
acidic conditions, this derivative of the terminal amino acid is cleaved as a thiazolinone 
derivative. The thiazolinone amino acid is then selectively extracted into an organic 
solvent and treated with acid to form the more stable phenylthiohydantoin (PTH)-amino 
acid derivative that can be identified by high-pressure liquid chromatography (Scheme 
2.4). This procedure can then be repeated again to identify subsequent amino acids in the 
peptide sequence. 
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Scheme 2.4 Edman degradation method 
 
Iterative N-terminal chemical degradation cycles yielded direct positional amino acid 
information.  Each degradation cycle produced one PTH-amino acid (PTH = 
phenylthiohydantoin) product that was analyzed by C18 HPLC and identified by retention 
time as compared with PTH-amino acid standards. 
2.6.2 Custom Edman Degradation.  A custom gradient was designed to allow 
for elution of the artificial amino acids, characterization of retention times, and 
confirmation of their incorporation in the in situ library.  To allow for resolution of 
artificial azide-containing amino acids by Edman degradation, the Pulsed-Liquid cLC 
extended method was utilized (Figure 2.5).  It includes a modified gradient, Normal 1 
cLC extended (Figure 2.6), and a flask cycle extended by 5 min (Figure 2.7). 
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Figure 2.5 Pulsed-Liquid cLC extended method 
 
 
 
Figure 2.6 Normal 1 cLC extended gradient  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Final steps of flask normal extended flask cycle 
 
The Edman traces corresponding to elution of Az2, Az4, Az6 and Az8 are shown 
in Figure 2.8 and demonstrate a 6 min retention time increase for every two methylene 
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units added to the azidoalkyl side chain.  Fmoc-Az2-OH was synthesized according to 
literature protocol,42 while Fmoc-Az6-OH was synthesized according to Scheme 2.2. 
 
 
 
 
 
 
 
 
 
Figure 2.8 Edman traces for artificial azide-containing amino acids 
 
Also, we performed a sequencing calibration for the in situ click hit using a 
commercially available 4-azidophenylalanine (Phe-N3) and an alkynyl inhibitor against 
bCAII.  The shift in retention is indicative of the click conjugation of the azide and 
alkyne species (Figure 2.9). Note that dptu is a side product of Edman sequencing.   
 
Figure 2.9 Edman sequencing calibration for the in situ click hit 
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2.7 Bulk Peptide Synthesis 
Bulk synthesis of hit peptide sequences was performed on either Fmoc-Rink 
amide MBHA or 2-chlorotrityl chloride resins, on a typical resin scale of 0.3 g per 
sequence, using standard coupling chemistry. Hits were re-synthesized to contain the 
appropriate artificial amino acid (azide/acetylene) linkers at their termini to make them 
suitable for click chemistry. Biligand and triligand were synthesized in bulk and 
preassembled using Scheme 2.3.  Crude peptides were precipitated with ether, and then 
purified to > 98% by HPLC (Beckman Coulter System Gold 126 Solvent Module and 
168 Detector, Fullerton, CA) on a C18 reversed phase semi-preparative column 
(Phenomenex Luna 10 µm, 250 × 10 mm).  The pure peptides were used for screens, 
affinity measurements, and binding assays.  Hit peptide sequences were also re-
synthesized on TentaGel S-NH2 on a similar resin scale, and used for on bead binding 
assays. 
 
2.8 Conclusion 
 Protein capture agents are constructed from peptide ligands, each of which is 
constructed from a unique set of amino acids, including nonnatural amino acids and 
artificial amino acids.  Artificial amino acids are synthesized so peptide ligands can be 
chemically functionalized with an azide (-N3) or acetylene (-C≡C-H) group serving as 
handles for click chemistry.  All of these amino acids are synthetically incorporated into 
peptides or polypeptides on beads using standard amino acid coupling chemistries. Using 
standard screening methods, the anchor, biligand, and triligand hits can be obtained and 
decoded by Edman degradation as shown in the last section of this chapter. 
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3.1 Introduction 
Chapter 3 describes an effective and generalized in situ click chemistry catalyzed 
approach using peptide ligands towards a model protein biomarker, bovine carbonic 
anhydrase II (bCAII). Carbonic anhydrase II is from a family of metalloenzymes that 
catalyze the reversible hydration of carbon dioxide. This protein has been used for 
studying protein-ligand interactions and it is a demonstrated receptor for bivalent 
ligands.1–5 In addition, expression of human carbonic anhydrase II (hCAII) is induced in 
the endothelium of neovessels in melanoma and renal and other cancers.6 Furthermore, 
CA II represents a major target antigen stimulating an autoantibody response in 
melanoma patients,7 and it is also potentially a therapy target for glial tumors.8 In this 
work, a triligand peptide capture agent was developed for bCAII and hCAII, which 
exhibited 64 and 45 nM binding affinities, respectively, by the sequential in situ click-
catalyzed assembly of three 7-mer peptide ligands (Scheme 3.1).    
 
Scheme 3.1 Preparation of protein catalyzed, multi-ligand capture agents 
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A completely random OBOC library of 22-mer peptides would be impractical for 
constructing and identifying the protein capture agent.  We further report that this 
triligand capture agent can detect bCAII and the hCAII from a serum consisting of 
multiple naturally occurring proteins.  These data suggest that triligands (and higher-order 
multi-ligands) assembled by in situ click chemistry will be a great source of robust and 
specific capture agents for in vitro diagnostics.  Our generalized methods should serve as 
the basis for inexpensive capture agent development for any protein.  This is of particular 
interest for proteins that do not respond well to traditional capture agents.   
 Herein, I describe, step-by-step, the screens and results associated with 
developing an anchor ligand, biligand, and triligand.  Binding affinity and selectivity 
measurements are also covered in this chapter.  Appendix B gives the complete structures 
of biligands and triligands, along with mass spectrum analysis. Attached to Appendix C 
is our recent literature paper: “Iterative In Situ Click Chemistry Creates Antibody-Like 
Protein-Capture Agents,” that can be further reviewed. 
 
3.2 Peptide Library Construction 
One-bead one-compound (OBOC) peptide libraries were synthetically 
constructed and discussed in Section 2.3.  Table 3.1 shows the specific libraries that were 
fabricated and used for screening against bCAII. 
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Table 3.1 Libraries used in this study† 
 Formula Components # of unique 
sequences 
A x1x2x3x4x5 xi = 19 D-amino acids 
(no D-Cys) 
2,476,099 
B x1x2x3x4x5x6 xi = r, k, l, w, f, h, y 117,649 
C Azn-x2x3x4x5x6-Azn xi = 19 D-amino acids 
(no D-Cys) 
Azn = 1/3 Az4, 1/3 Az8, 
1/3 nothing 
22,284,891 
D x1x2x3x4x5x6-Tz1-kfwlkl xi = k, l, w, f, i, g, v 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on x6) 
E x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
xi = d, r, s, w, G, f, l 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on l) 
Tz2 = triazole formed between Az4 (on terminal x2) and D-Pra (on k) 
F Az4-x2x3x4x5x6x7 3200 
G x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
x2 = r, n, l, i; 
x3 = w, f, l, i; 
x4 = r, w, f, l, i; 
x5 = w, f, v, l; 
x6 = r, w, f, l, k; 
x7 = f, r 
3200 
† Randomized positions are denoted by x (for D-amino acids) and Azn (for azide-
containing artificial amino acids). 
 
3.3 Screening and Results for Anchor Ligand  
The first peptide, or anchor ligand, was selected from a 2-generation library screen (An1, 
An2, An2b, Table 3.1). Using the OBOC combinatorial library methodology, a 
randomized library of pentapeptides consisting of 2,476,099 D-peptide compounds was 
synthesized manually by a split-and-mix synthesis approach as previously discussed in 
Chapter 2. An approximately ten fold excess of beads was utilized to fabricate the peptide 
library. This pentapeptide library was expected to afford enough diversity to discriminate 
between weak and strong binders, and the sample size was large enough to ensure that 
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there will be some lead compounds.  The library was also simple enough to manually 
prepare on the bench-top, and was readily modified with azide-containing amino acids. 
3.3.1 First-Generation Screen for Anchor Ligand.  For the first screen (An1), 
Library A was screened with 100 nM bCAII protein, labeled with Alexa Fluor 647 
succinimidyl ester (Figure 3.1).   
 
Figure 3.1 Screening for anchor ligand 
 
The red Alexa Fluor 647 dye was chosen for protein labeling due to the low 
autofluorescence of the TentaGel bead at these wavelengths. The dye was conjugated to 
the bCAII protein at low level (< 3 fluorophores/protein) to minimize interference of the 
fluorophore with real binding interactions. Thus, the “hit” beads were identified by their 
fluorescence.  The brightest fluorescent beads (< 0.02% of library) were manually 
separated from the non-hit beads.  After removing the protein from the beads using 7.5 M 
guanidine hydrochloride (pH 2.0), the hit peptide-beads were sequenced by Edman 
degradation9 (Table 3.2) and analyzed by a histogram correlating the frequency of amino 
acid occurrence vs amino acid identity (Figure 3.2).  The results suggest that 
basic/charged (k, r) and aromatic residues (y, f, w) are important amino acids in an 
anchor ligand for bCAII. 
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Table 3.2 First-generation anchor ligand screen An1 (100 nM) results 
 X1 x2 x3 x4 x5  x1 x2 x3 x4 x5 
hit1 r r y h r hit27 w r -- y r 
hit2 m/v r w k r hit28 h r w r r 
hit3 k r w y y hit29 w y r k r 
hit4 w k k k w hit30 l r f r r 
hit5 h f f f r hit31 w k r k k 
hit6 s r -- r r hit32 r r r w s/m 
hit7 r r w h y hit33 r r k f w 
hit8 r k w w w hit34 r r w r y 
hit9 r w s f r hit35 w r h y k 
hit10 r r G w r hit36 r r y f r 
hit11 G f r r w hit37 w r k w r 
hit12 r t r r w hit38 w y -- r r 
hit13 m r w k r hit39 y r r r h 
hit14 y r k r w hit40 y r r r w 
hit15 a -- -- -- -- hit41 p f y w r 
hit16 r r i r w hit42 k y w r k 
hit17 -- -- k/l w -- hit43 r y w h k 
hit18 r w -- -- r hit44 r w h w n 
hit19 k/l r -- w r hit45 r h f h h/f 
hit20 w r f r y hit46 r r -- h r 
hit21 d/p y y r r hit47 r y r r r 
hit22 r y w k k hit48 y f h h/w w 
hit23 k/l r r r w hit49 r r r w y 
hit24 y r r k w hit50 w r r r r/-- 
hit25 r k/l f y r hit51 r w k f h 
hit26 r w w k r 
 
 
Figure 3.2 Histogram for 51 hit sequences isolated from screen An1 (first-generation 
anchor ligand screen) 
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3.3.2 Re-Screening for Anchor Ligand with a Focused Library.  A second, 
more focused library (Library B, Table 3.1) of 117,649 D-peptide compounds was 
constructed from the most commonly occurring amino acids (r, k, l, w, f, h, y), as 
identified from screen An1, but expanded into a 6-mer peptide, and screened under 50 
nM bCAII (An2a) and 8 nM bCAII (An2b) conditions. The results of the second-
generation anchor ligand screens are shown in Tables 3.3 and 3.4.  The hit rates were 
0.09% and 0.05% for 50 nM and 8 nM, respectively.    
Table 3.3 Second-generation anchor ligand screen An2a (50 nM) results 
 x1 x2 x3 x4 x5 x6 
hit1 y r w f k f 
hit2 h/r h/r f l l/r r 
hit3 f r f y y r 
hit4 h/r f f k l -- 
hit5 k l f l k l 
hit6 l f l w l k 
hit7 f f f r y -- 
hit8 h/r f f f r -- 
hit9 r w w l k f 
hit10 h/r f f r y y 
hit11 l k l f l k 
hit12 f r r w w k 
hit13 h/r y f f k l 
hit14 l k f f f k 
hit15 h/r f f r r -- 
 
Table 3.4 Second-generation anchor ligand screen An2b (8nM) results 
 x1 x2 x3 x4 X5 x6 
hit1 h l y f l r 
hit2 l k l w f k 
 
The more stringent screen yielded two hits, hlyflr and lklwfk.  From these two 
candidates, one peptide (lklwfk) was arbitrarily chosen as the starting point for an anchor 
ligand for use in the multi-ligand screens. 
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3.4 Binding Measurements for Anchor Ligand by Fluorescence Polarization   
The anchor peptide lklwfk was then functionalized with an acetylene (-C≡C-H) at 
the C-terminus and produced in bulk quantities (see Section 2.7 for details) for affinity 
measurements by fluorescence polarization (using a fluoresceinated peptide). The N-
terminus of the anchor ligand was labeled with fluorescein isothiocyanate (FITC) 
following published protocols.10 After resin cleavage, the crude fluoresceinated anchor 
ligand was precipitated with ether and then purified to > 98% by C18 reversed-phase 
HPLC. 
Luminescence spectra were recorded by Fluorolog2 spectrofluorimeter (Jobin 
Yvon, Longjumeau, France) in the Beckman Institute Laser Resource Center (Pasadena, 
CA).  All samples contained 6 µM fluoresceinated anchor ligand and varying 
concentrations of bCAII (0.2 µM to 800 µM) in PBS (pH 7.4) + 3% (v/v) DMSO.  Stock 
protein and anchor ligand concentrations were verified by UV-Vis using ε280 (bCAII) = 
57,000 M-1cm-1 or ε494 (FITC, 0.1 N NaOH) = 68,000 M-1cm-1 for fluoresceinated anchor 
ligand.  Samples were excited at 488 nm (2 nm band-pass), and luminescence spectra 
were obtained between 500 nm and 700 nm (4 nm band-pass).  All measurements were 
taken at 2 nm intervals with 0.5 s integration times at 25 °C.  All luminescence spectra 
were subjected to background subtraction. 
The ratio of sensitivities (G) for the vertically and horizontally plane-polarized 
light in the system was calculated by the equation G=IHH/IHV using the IHH and IHV 
luminescence spectra obtained from a peptide-only sample.  The luminescence spectra 
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IVV and IVH were integrated, and the fluorescence polarization value (P) was obtained by 
applying Equation 1. 
VHVV
VHVV
GII
GII
P
+
!
=   (1)   
   
The polarization values were fitted with a sigmodial curve using the logistical 
equation (Origin 6.1, Northampton, MA), 
2p
0
21 A
)(x/x1
AA
y +
+
!
=   (2)       
where A1 = initial y value, A2 = final y value, p = power, and x0 = center. 
By this method, a 500 µM affinity was measured for the fluoresceinated anchor 
ligand lklwfk-(D-Pra) (Figure 3.3).  However this value is an estimate, since weak 
affinities are hard to quantify.   
 
Figure 3.3 Fluorescence polarization binding isotherm for the anchor ligand lklwfk-(D-
Pra), showing KD ≈ 500 µM.  
 
Surface plasmon resonance (SPR) was also used to measure the affinity of bCAII with 
lklwfk-(D-Pra), and a similarly low affinity was recorded (at least > 10 µM, data not 
shown). 
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3.5 In Situ Click and On Bead Biligand Screens and Results 
A biligand is constructed of a 2o ligand that is covalently attached, via a 1,2,3-
triazole linkage, to the anchor ligand. Two screening strategies, namely in situ (Scheme 
3.2A) and on bead (Scheme 3.2B) screens, were utilized to screen for biligand 
candidates. 
 
Scheme 3.2 A) In situ biligand screen schematic, illustrating the on bead biligand 
synthesis catalyzed by bCAII.  B) On bead biligand library schematic 
  
3.5.1 First-Generation In Situ Biligand Screen.  Based upon the in situ click 
chemical reactions reported by the Sharpless group,11–17 the anchor ligand and protein are 
in solution, and the library of 2o ligands is on the bead.  Only those 2o ligands that bind 
with bCAII and are in close proximity with the anchor peptide, and are in the correct 
orientation, will react to form the 1,2,3-triazole product.  In the in situ click biligand 
screen (Bi1), a solution of 50 nM bCAII-Alexa Fluor 647 was pre-incubated with the 
anchor ligand, 100 µM lklwfk-(D-Pra), for 2 hours at 37 °C in PBS (pH 7.4) + 1% 
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DMSO (v/v).  The anchor/protein solution was added and incubated with a large and 
comprehensive, azide-modified OBOC Library C (22,284,891 element, 4× sampled, 
Table 3.1) for 48 hours at 37 °C, with shaking to form an in situ biligand.  For this screen, 
excess anchor ligand is supplied so that it is noncovalently attached to its binding site on 
every protein molecule.  The bCAII protein target acts as a catalyst for the click reaction 
by orienting the anchor ligand and the secondary ligand correctly with respect to each 
other and the protein surface.  The screened beads were washed with 3 × 5 mL PBS (pH 
7.4), then 7 × 5 mL water.  The beads were imaged for fluorescence using the protocol 
outlined before.  Hits, representing potential biligands formed in situ, were manually 
selected by micropipette and processed with guanidine hydrochloride to remove bound 
protein.  These beads were then sequenced by Edman degradation. 
 The hit beads (0.007% hit rate) from the in situ screen (Scheme 3.2A) were 
sequenced to identify 2o ligand candidates, from which a biligand could be separately 
prepared.  The results from Edman degradation of the 23 in situ hits are presented in 
Table 3.5.   
Table 3.5 In situ biligand screen Bi1 (50 nM) results 
 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 k i w i G   
hit2 Az8 r l w v G Az4 
hit3 Az8 r r r k r Az8 
hit4 Az4 l l v i k Az4 
hit5 Az4 m i l i k   
hit6 Az8 i i i m r Az4 
hit7 Az8 i i i w r Az8 
hit8 Az4 n v i i f   
hit9 Az4 i f l v k Az8 
hit10 Az4 k i w i G Az8 
hit11 Az4 r r k f r Az8 
hit12 Az4 r v w l r Az8 
hit13 Az8 k y r r r Az4 
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hit14 Az8 r r k v w Az4 
hit15 Az4 i f l v k Az8 
hit16   k r k r f Az4 
hit17 Az8 k i w i k   
hit18 Az8 y r k f k   
hit19 Az4 i f f r v Az8 
hit20   a r k k y Az4 
hit 21   r k r t i Az4 
hit 22 Az8 k m v f k Az4 
hit23 Az4 l i m k i Az4 
 
An extremely high level of sequence homology is observed.  Three almost identical 
peptides, AznkiwiGAzn, are highlighted above.  Note also that all of the peptides contain 
at least one azido group, although, statistically, over 1/3 of the OBOC library does not 
contain azido groups at the 1 or 7 positions.  The high sequence homology, coupled with 
the persistence of azido groups in the peptide, provides strong evidence that the in situ 
OBOC screen worked to produce a biligand.  
3.5.2 First-Generation On Bead Biligand Screen.   In the second approach, the 
anchor ligand and cognate library of 2o ligands are preassembled as complete biligands 
on bead.  The protein is screened against the library of biligands in a stringent screen, in 
order to choose the best biligands.  On bead (Scheme 3.2B) biligand screens (Bi2a and 
Bi2b) were carried out utilizing a focused biligand library (Library D; 117,649 peptides, 
Table 3.1) that was prepared based upon the sequencing results from screen Bi1.  The 
1,2,3-triazole linkage in this library was prepared using the classical click reaction 
between artificial amino acid Az4 and D-Pra described earlier in Chapter 2.  Az4 was 
chosen as the optimal azide linker length based on sequence homology found among the 
in situ biligand hits.  This library was limited to a smaller size to ensure high purity of 
full-length biligand sequence on every bead.  To block nonspecific protein binding, the 
library was first incubated in PBS (pH 7.4) + 0.1% Tween 20 + 0.1% bovine serum 
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albumin (BSA) + 0.05% NaN3 (PBSTBNaN3) for 1 hour, with shaking.18 Following this 
pre-blocking step, the library was washed with 3 × 5 mL PBSTBNaN3.  The bCAII-
Alexa Fluor 647, at 50 nM (Bi2a) and 10 nM (Bi2b) in 4 mL PBSTBNaN3, was 
incubated with the library for 17 hours at 25 °C, with shaking.  The screened beads were 
washed with 3 × 5 mL PBSTBNaN3, then 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 20, and 
finally 6 × 5 mL PBS (pH 7.4).  The beads were imaged for fluorescence, and the hits 
were selected by micropipette.  After washing the hits to remove bound protein, their 
sequences were determined by Edman degradation (Tables 3.6 and 3.7). 
Table 3.6 On bead biligand screen Bi2a (50 nM) results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x1 x2 x3 x4 x5 x6 
hit1 f k l w i k 
hit2 v w l w G G 
hit3 f w f w G G 
hit4 k w f w G G 
hit5 f k l w l k 
hit6 k w f w G G 
hit7 w w i w G G 
hit8 k G w l w G 
hit9 k l w i w G 
hit10 l w i w G l 
hit11 f k G f l i 
hit12 f w i w G k 
hit13 l w l w G i 
hit14 i i v l w k 
hit15 l i i f v  
hit16 v k f i l l 
hit17 l G f f w i 
hit18 k k l k k l 
hit19 f k l w i k 
hit20 w i w G G f 
hit 21 f f l l v k 
hit 22 k f k f w k 
hit23 l i k l f v 
hit24 l w f w G v 
hit25 f w f w G i 
hit26 G w f w G v 
hit27 G w i w G k 
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Table 3.7 On bead biligand screen Bi2b (10 nM) results 
 x1 x2 x3 x4 x5 x6 
hit1 k w i w G w 
hit2 k w i w G v 
hit3 k w l w G l 
hit4 k w i w G l 
hit5 k w i w G w 
hit6 k w l w G l 
hit7 G w i w G i 
hit8 k i f k i f 
 
The on bead Bi2a and Bi2b screens (0.07% and 0.008% hit rates, respectively) 
again yielded a striking sequence homology, suggesting the consensus sequence 
kwx3wGx6 (where x3 = hydrophobic amino acid, x6 = any amino acid).  Two secondary 
ligand candidates from the on bead screen were repeated several times, namely kwlwGl 
and kwiwGw. 
From the on bead and in situ screens, three candidate biligands— kwlwGl-Tz2-
kfwlkl, kwiwGw-Tz4-kfwlkl, and lklwfk-Tz5-kiwiG [where Tz4 = triazole formed 
between Az4 (on terminal k) and D-Pra (on w), and Tz5 = triazole formed between Az4 
(on terminal k) and D-Pra (on k)]— were synthesized in bulk on 2-chlorotrityl chloride 
(1.6 mmol/g) resin (Anaspec, San Jose, CA) using Scheme 2.3.  The biligand was 
released either as the fully deprotected peptide by cleavage with 95:5 TFA:water (+ 2 mol 
equiv TES per side chain protecting group), or as the fully protected peptide by cleavage 
with 99:1 DCM:TFA (García-Martín et al. 2007).  
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3.6 Binding Measurements for Biligand by Surface Plasmon Resonance (SPR)  
Immobilization and biligand sensing experiments were performed on a Biacore 
T100 SPR (California Institute of Technology Protein Expression Center, Pasadena, CA).  
Two flow cells of the biosensor surface (Biacore CM5) were immobilized with bCAII 
following standard procedures using NHS/EDC and 0.25 mg/mL bCAII prepared in 10 
mM sodium acetate (pH 5.0) buffer.12 The remaining two flow cells were left 
underivatized, to correct for changes in bulk refractive index and to assess nonspecific 
binding.  Biligand samples were injected in a concentration series (5 µM to 2 nM) at 100 
µL/min flow rate for 120–180 s across the four flow cells. 
 All three biligands— kwlwGl-Tz2-kfwlkl, kwiwGw-Tz4-kfwlkl, and lklwfk-
Tz5-kiwiG— were synthesized in bulk (as described above) and their binding affinities 
for bCAII were measured using SPR.  The binding responses reveal 10-6 M affinity for 
the biligands toward bCAII proving that the bead-based in situ screen and the on bead 
biligand library screen converge on similar biligand sequences with similar affinities.  
The SPR data for the best-binding biligand kwlwGl-Tz2-kfwlkl is shown in Figure 3.4B, 
and its chemical structure is pictured in Figure 3.4A. The biligand affinity fit of KD ≈ 3 
µM is two orders of magnitude greater than the affinity for the 1o ligand alone, meeting 
our goal of affinity enhancement.   
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Figure 3.4 A) Biligand chemical structure.  B) SPR response sensorgrams obtained with 
increasing concentration of the biligand kwlwGl-Tz2-kfwlkl (2 nM to 5 µM) demonstrate 
a 3 µM binding affinity to bCAII.  
 
3.7 In Situ Click and On Bead Triligand Screens and Results  
A triligand capture agent was identified in a similar way to the biligand, but with 
two exceptions.  First, a modified form of the best-binding biligand (D-Pra)-kwlwGl-
Tz2-kfwlkl served as the anchor peptide.  Second, within the constraints of the OBOC 
libraries we could reasonably prepare, we attempted a direct comparison of in situ (Tri1) 
and on bead (Tri2) first-generation screens. The notable difference between these screens 
was the chemical diversity of the OBOC libraries.   
3.7.1 First-Generation In Situ Triligand Screen.  For the first generation in situ 
screen Tri1, a solution of 10 nM bCAII-Alexa Fluor 647 was pre-incubated with 100 µM 
biligand anchor (D-Pra)-kwlwGl-b-kfwlkl for 2 hours at 25 °C in PBSTBNaN3 (pH 7.4) 
B) 
A) 
 
2°  
    1°   
 
Tz1 
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+ 1% DMSO (v/v).  After blocking the library in PBSTBNaN3 (pH 7.4) for 1 hour, with 
shaking, the anchor/protein solution was added to the bead library C (4 g, ~ 2,250,000 
beads) and incubated for 15 hours at 25 °C, with shaking, to form an in situ triligand. 
Notice that the same, comprehensive 2×107 element OBOC Library C that was utilized 
in screen Bi1 was applied again here, demonstrating the versatility of this type of general 
library.  The screened beads were washed with 3 × 5 mL PBSTBNaN3, then 3 × 5 mL 
PBS (pH 7.4) + 0.1% Tween 20, and finally 6 × 5 mL PBS (pH 7.4).  The beads were 
then imaged for fluorescence.  Hits, representing potential triligands formed in situ, were 
selected manually by micropipette.  The selected beads were washed to remove bound 
protein and the sequences of these hits were obtained by Edman degradation (Table 3.8). 
Table 3.8 First-generation in situ triligand screen Tri1 (10 nM) results 
 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 n i i i v  
hit2 Az4 i i l l k Az4 
hit3 Az4 n i i v l  
hit4 Az4 n m i f l Az4 
hit5 Az4 n v l v l  
hit6 Az4 n l i l f Az4 
hit7 Az4 n l i l f Az4 
hit8 Az8 r l w i r Az4 
hit9 Az4 n l i v f Az4 
hit10 Az4 r m w v k Az8 
hit11 Az4 i i l l k Az8 
hit12 Az4 i l v v r Az4 
hit13 Az4 n l l f l Az4 
hit14 Az4 n i i v y  
hit15  m k r k k Az8 
hit16 Az4 i l i r w Az4 
hit17 Az8 i i v f r Az8 
hit18 Az8 y f t r r  
hit19 Az4 n m i i v Az4 
hit20 Az8 i l i a k Az4 
hit21 Az4 i l l r w  
hit22 Az8 i v v f r Az4 
hit23 Az4 l l l v k Az4 
hit24 Az4 k v w i k Az4 
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3.7.2 First-Generation On Bead Triligand Screen.  For the on bead screen 
Tri2, the difficulty of manually synthesizing a high-purity 22-mer OBOC library meant 
that we limited the library to a smaller number of amino acids (d, r, s, w, G, f, l), chosen 
to represent as high a chemical diversity as possible for a limited library size (~ 105–106 
peptides).  Screens were conducted using Library E (40 mg, ~ 120,000 beads, Table 3.1) 
in a polypropylene fritted tube.  To block nonspecific protein binding, the library was 
first incubated in PBSTBNaN3 (pH 7.4) for 1 hour, with shaking.  Following this pre-
blocking step, the library was washed with 3 × 5 mL PBSTBNaN3.  The bCAII-Alexa 
Fluor 647, at 10 nM dilution in 4 mL PBSTBNaN3, was incubated with the library for 17 
hour at 25 °C, with shaking.  The screened beads were washed with 3 × 5 mL 
PBSTBNaN3, then 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 20, and finally 6 × 5 mL PBS 
(pH 7.4).  The beads were imaged for fluorescence, and the hits were selected by 
micropipette.  After washing the hits to remove bound protein, their sequences were 
determined by Edman degradation (Table 3.9). 
Table 3.9 First-generation on bead triligand screen Tri2 (10 nM) results 
 x2 x3 x4 x5 x6 x7 
hit1 r l w l r f 
hit2 r l w l r l 
hit3 r f f f r f 
hit4 r l f l r f 
hit5 l f f w f r 
hit6 l w f f f r 
hit7 l f l w f r 
hit8 l w l f f r 
hit9 l f f w l r 
hit10 r r r l w r 
hit11 r l w l r f 
hit12 w r r r r w 
hit13 r f r f r w 
hit14 f w f f w r 
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There was also a high sequence homology among the triligand sequences.  The in 
situ screen Tri1 yielded a 0.007% hit rate that suggested sequences Az4-nlilfx7 and Az4-
nlivfx7 (where x7 = any amino acid).  The on bead screen Tri2 resulted in a 3o ligand 
candidate, Az4-rlwlrx7, whose motif was repeated three times.  Since the on bead Tri2 
screen was by no means comprehensive, it is not surprising that a somewhat different 3° 
ligand consensus was reached. 
3.7.3 Azide-Free In Situ Triligand Screen.  To further understand the effect of 
the azide-acetylene interaction on the in situ results, a third in situ screen (TriX) was 
conducted under otherwise identical conditions as screen Tri1, except for the substitution 
of azide-rich Library C with the azide-free Library A, thus prohibiting the formation of 
a triazole linkage.    While this control in situ screen TriX displayed a nearly identical hit 
rate (0.007%), a completely different sequence homology was reached as (d/a/s)wwx4x5 
(where x4,x5 = any amino acid) (Table 3.10 and 3.11).  The remaining hit sequences from 
screen TriX display significant variation and high numbers of repeating arginine 
residues, indicative of nonspecific anionic-cationic interactions.19  This argues the 
importance of the azide-acetylene interaction in the in situ library selection for choosing a 
specific ligand, whose specificity is a consequence of the in situ click conjugation. 
Table 3.10  Azide-free in situ triligand screen TriX results (control) 
 x1 x2 x3 x4 x5 
hit1 w f r r r 
hit2 s w v w G 
hit3 p v y f w 
hit4 d d y w G 
hit5 i w a y w 
hit6 d n w G f 
hit7 a w w a t 
hit8 r f r r f 
hit9 d w w h t 
hit10 r f r w r 
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hit11 d e w p h 
hit12 a w w l w 
hit13 a w w a y 
hit14 d k k i y 
hit15 d w s i e 
hit16 s w w f y 
hit17 d w l r y 
hit18 s w a f y 
hit19 d l f l w 
hit20 d w a t w 
hit21 f k y r s 
hit22 d q r w r 
hit23 i w s t h 
hit24 l i v m w 
 
 
Table 3.11 Position-dependent histograms for the first-generation in situ click screens, 
for peptides with and without an azide-containing amino acid, to generate a triligand.  
The final, consensus triligand sequence is indicated by red font. For the in situ screen, 1/3 
of the beads had no azide at the x1 or x7 positions, but all hit beads contained an azide.   
Sample size: in situ and in situ no azide n=24 
 
3.7.4 Re-Screening for Triligand Ligand with Focused Libraries.  Second-
generation in situ (screen Tri3) and on bead (screen Tri4) triligand screens were 
conducted using Libraries F and G, respectively (Table 3.1).  Each Library F and 
Library G included all the high-homology amino acids isolated by the first-generation 
triligand screens. The second-generation screens were used to determine whether a single 
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triligand capture agent could be deduced by screening a single, highly focused triligand 
library.  
Both triligand screening strategies allowed for isolation of hits at much lower 
bCAII-Alexa Fluor 647 concentrations, as low as 500 pM for the in situ library and 250 
pM for the on bead library, compared to the biligand screens.  In the second-generation in 
situ click triligand screen, a solution of 500 pM bCAII-Alexa Fluor 647 was pre-
incubated with 100 µM Biligand Anchor (D-Pra)-kwlwGl-b-kfwlkl for 2 hours at 25 °C 
in PBSTBNaN3 (pH 7.4) + 1% DMSO (v/v).  After blocking the library in PBSTBNaN3 
(pH 7.4) for 1 hour, with shaking, the anchor/protein solution was added to the focused 
bead Library F (3200 D-peptide compounds, 1 mg, ~ 3200 beads) and incubated for 18 
hours at 25 °C, with shaking, to form a triligand.   
In the second-generation on bead triligand screen, screens were conducted using 
the focused Library G (1 mg, ~ 3200 beads) for 18 hours at 25 °C, with shaking. 
Library G was constructed using exactly the same constituent amino acids as Library F, 
but with the biligand anchor covalently attached to the end of the library via the Cu(I)-
catalyzed click reaction.  In both cases, the screened beads were washed with 3 × 5 mL 
PBSTBNaN3, then 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 20, and finally 6 × 5 mL (PBS 
pH 7.4).  The beads were then imaged for fluorescence.  Hits, representing potential 
triligands formed in situ, were selected manually by micropipette.  The selected beads 
were then processed to remove bound protein, and the sequences of these hits were 
obtained by Edman degradation (Tables 3.12 and 3.13).  
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Table 3.12 Second-generation in situ triligand screen Tri3 (500 pM) results 
 x2 x3 x4 x5 x6 x7 
hit1 n l I v f r 
hit2 n l i v l r 
hit3 n i i l l r 
hit4 i l f l f r 
hit5 n l i v l r 
hit6 n i i l w r 
hit7 n l i v f r 
hit8 n l i v f r 
 
 
Table 3.13 Second-generation on bead triligand screen Tri4 (250 pM) results 
 x2 x3 x4 x5 x6 x7 
hit1 n l i v f r 
hit2 n l i v f r 
hit3 n i i v f r 
hit4 n i i v f r 
hit5 n i i l l r 
hit6 n l i v l r 
hit7 n l i v f r 
 
Both the in situ (Tri3) and on bead (Tri4) screens yielded a single 3o ligand 
sequence of Az4-nlivfr.  The fact that this same consensus sequence was identified by 
both an on bead and an in situ screen (each designed to sample the same chemical space, 
albeit via different paths) provides further confirmation of the equivalence of the two 
types of screens.   
The triligand— rfviln-Tz2-kwlwGl-Tz1-kfwlkl— was synthesized by the click 
reaction between the fully protected biligand anchor (0.274 g, 0.1 mmol, > 98% HPLC) 
and bead-bound 3° ligand Az4-nlivfr (0.1 g, 0.07 mmol) using copper iodide (0.021 g, 
0.1 mmol) and L-ascorbic acid (0.020 g, 0.1 mmol) in DMF/piperidine (8/2) at 25 °C 
(Scheme 2.3).   
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3.8 Binding Measurements for Triligand using SPR    
3.8.1 Protein.  Human carbonic anhydrase II (hCAII, C6165), from human 
erythrocytes, lyophilized powder, was purchased from Sigma-Aldrich (St. Louis, MO) 
and used in affinity and selectivity studies.  Both bCAII and hCAII were tested by SDS 
gel electrophoresis, and confirmed to display a single band corresponding to 29,000 Da. 
3.8.2 SPR. The triligand, rfviln-Tz2-kwlwGl-Tz1-kfwlkl, (chemical structure 
shown in Figure 3.5A) was synthesized in bulk and its binding affinity for both bCAII 
and hCAII was measured using SPR.  These affinity measurements utilized a Biacore 
T100 SPR (California Institute of Technology Protein Expression Center, Pasadena, CA).  
One flow cell of the biosensor surface (Biacore CM5) was immobilized with bCAII 
following standard procedures using 0.25 mg/mL bCAII prepared in 10 mM sodium 
acetate (pH 5.0) buffer and a 1:1 solution of 0.1 mM NHS and 0.4 mM EDC.20 Similarly, 
a second flow cell was immobilized with hCAII following standard procedures using 0.25 
mg/mL hCAII prepared in 10 mM sodium acetate (pH 5.5) buffer.  An immobilization 
level of 5000 RU was achieved using a flow rate of 100 µl/min over 420 s.  The 
remaining two flow cells were left underivatized, to correct for changes in bulk refractive 
index and to assess nonspecific binding.  The running buffer was prepared to contain 10 
mM HEPES + 150 mM NaCl + 0.05% Tween20 + 3% DMSO, and this buffer was used 
for all experiments.   
Prior to the peptide analyte experiment, 8 ‘startup’ cycles (running buffer alone) 
were completed to ensure that the instrument had a stable baseline.  Response data were 
then collected for biligand samples over increasing concentrations (2 nM to 5 µM) at 100 
µL/min flow rate, 120–180 s contact time, and 300 s dissociation phase across the four 
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flow cells.  Similarly, response data were collected for anchor ligands (300 nM to 9.4 
µM) and triligand (0.1 nM to 162 nM) over increasing analyte concentrations.  After 
subtracting the background response from the underivatized flow cell, the analyte 
response data was fitted for 1:1 binding affinity using the BiaEvaluation software. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 A) Triligand chemical structure.  B,C) SPR response sensorgrams were 
obtained with increasing concentration of triligand (0.1 nM to 162 nM) and demonstrate 
45 nM and 64 nM affinities for human (B) and bovine (C) CA II, respectively.   
A) 
B) 
C) 
 
(a)
  
(a)
 
 
 
1° 
3° 
2° 
 hCAII 
 bCAII 
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Figures 3.5B and 3.5C show the SPR results for the triligand to be KD ≈ 45 nM (hCAII) 
and KD ≈ 64 nM (bCAII).  This represents a fifty fold affinity enhancement over the 
biligand.   The triligand was also shown to not bind to the enzymatically active site of 
bCAII by an activity assay using 4-nitrophenyl acetate (4-NPA) as chromogenic substrate 
(data not shown here).21 
 
3.9 Dot Blot Selectivity/Sensitivity Assays in Serum 
The sensitivity and selectivity of the multi-ligand (biligand and triligand) capture 
agents for b(h)CAII in complex environments were demonstrated through the use of dot 
blot experiments in 10% porcine serum.  For these tests, Biotin-PEG-NovaTag resin 
(0.48 mmol/g; Novabiochem) was utilized for bulk synthesis of C-terminal biotin-labeled 
multi-ligands.  After resin cleavage, the crude biotinylated multi-ligand was precipitated 
with ether and then purified to > 98% by C18 reversed-phase HPLC.  Antigens (bCAII 
and hCAII) were prepared as 2 mg/mL stocks in PBS (pH 7.4).  A dilution series of 
antigen was applied to a nitrocellulose membrane, typically ranging from 20 µg to 0.4 pg 
per spot.   The membrane was blocked at 4 °C overnight in 5% milk in Tris-buffered 
saline (TBS) [25 mM Tris, 150 mM NaCl, 2 mM KCl (pH 7.4)].  The membrane was then 
washed with 3 x 5 min TBS (pH 7.4).  The biotinylated triligand was prepared at 1 µM in 
10% porcine serum in TBS (pH 7.4) + 0.1% DMSO and incubated over the membrane 
overnight at 4 °C.  After washing with TBS (pH 7.4) for 1 hour, 1:3000 Streptavidin-
HRP (AbCam, Cambridge, MA) prepared in 0.5% milk/TBS (pH 7.4) was added to the 
membrane and incubated for 1 hour.  After washing with TBS (pH 7.4) for 1 hour, 
chemiluminescent reagents (SuperSignal West Pico Chemiluminescent Enhancer and 
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Substrate Solutions, Pierce, Rockford, IL) were incubated over the membrane and then 
immediately developed on film to determine binding.   
Figure 3.6A illustrates that the triligand is a suitable capture agent for detection of 
~ 20 ng antigen from 10% serum, and that the capture agent was specific for both the 
bovine and human forms of the enzyme.  Since bCAII and hCAII are 81.2% identical in 
sequence, similar binding sites are expected (PDB ID: 1CA2, 1V9E).  The commercial 
anti-bCAII was capable of detecting lower antigen (~ 1 ng).  However, this result cannot 
be directly compared to the triligand result, as this antibody is labeled with significantly 
more biotins per molecule (15–20 biotins/antibody), while the triligand is labeled with 
only 1 biotin per molecule.  When the biligand anchor (D-Pra)-kwlwGl-Tz2-kfwlkl was 
used as the capture agent in 0.1% serum, the sensitivity was reduced more than ten fold 
(Figure 3.6B).    
For comparison, the dot blot was completed in parallel using a commercial 
antibody as the capture agent.  The polyclonal rabbit anti-bCAII IgG, biotin conjugate 
(Rockland Immunochemicals, Gilbertsville, PA) was prepared at 1:4000 dilution and 
incubated as described above. Both the triligand and commercial antibody were tested for 
cross-reactivity with 1 µg human IL-2 (BD Biosciences, San Jose, CA) and 1 µg human 
TNFα (eBioscience, San Diego, CA), and no binding was detected (Figure 3.6C).  We 
also tested BSA as the antigen and similarly found no cross-reactivity. 
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Figure 3.6 A) Dot blot illustrating the limit of detection by the triligand for bCAII and 
hCAII in 10% serum.  B) When the biligand anchor is used as the capture agent in 0.1% 
serum, the sensitivity is reduced > ten fold. C) Dot blot illustrating the selectivity of the 
triligand, compared to a commercial antibody 
 
3.10 Conclusion  
This thesis demonstrated the development of a peptide capture agent with high 
affinity and selectivity against CAII through the conjugation of modest affinity peptides 
using in situ click chemistry.  An affinity enhancement due to in situ click conjugation 
was apparent starting from the level of the biligand screens.  Even for a weakly binding 
anchor ligand (KD ≈ 500 µM), biligand screens yielded high hit homologies and affinities 
between 3 and 10 µM.  Both types of biligand screens, in situ and on bead, demonstrated 
this effect, suggesting that although the mechanism of the selection is different, the hits 
identified are essentially equivalent.  When the peptide ligand becomes larger than a 10–
15mer, the OBOC library size is practically limited to < 1 million sequences, and the in 
situ screen becomes the only way to sample increasing diversity and length.  
B) 
A) 
 
C) 
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Comprehensive in situ libraries are also quite valuable in their versatility, as they can be 
used in more than one screen and with more than one protein target, if synthesized at a 
large enough scale to accommodate multiple experiments.  At the triligand level, a 
similar concept was explored.  While the in situ library was still comprehensive, it 
utilized the basis of the biligand anchor to direct the assembly of the triligand.  Based on 
analysis of sequence homology, we discovered that the final triligand capture agent 
reflects in situ assembly, as the on bead triligand library was not comprehensive.  The 
final triligand peptide capture agent was demonstrated to bind to bCAII and hCAII with 
affinities of KD ≈ 64 nM and KD ≈ 45 nM, respectively, and it was proven to be a 
selective binder for the enzyme as illustrated by dot blot.  The small size of the triligand 
peptide capture agent is expected to increase sensitivity of CAII detection in surface-
based diagnostic assays.   
The advantage of this approach is multifold.   First, each multi-ligand is 
comprised of two or more ligands, and each ligand is a peptide-like molecule, comprised 
of natural, artificial, or nonnatural amino acids and other organic molecule building 
blocks. Chemical and biochemical stability, water solubility, thermal stability, and other 
desired characteristics can be custom designed into the multi-ligand.  Also, multi-ligand 
capture agents produced in this way do not denature, as antibodies do, since their affinity 
and selectivity are not contingent upon their folded structure.  Next, as the number of 
ligands comprising the multi-ligand protein capture agent is increased, the selectivity and 
affinity of the multi-ligand for the protein of interest rapidly increases. Tetraligands, 
pentaligands, etc., are all possible using the same concepts.  Moreover, the target protein 
itself is utilized as a catalyst to assemble its own multi-ligand capture agent.  The 
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individual ligands themselves are specifically designed for this catalytic process.   No 
previous knowledge is needed of the capture agent and the protein of interest.  
Furthermore, amino acid building blocks are readily available, and chemical synthesis of 
peptides in relatively large quantities using conventional amide coupling chemistries is 
not difficult. This implies that the peptide capture agents may be produced in multi-gram 
quantities at low cost. Since straightforward chemistries are implemented at every stage in 
the process, we expect to use this as a general and robust platform for high-throughput 
capture agent discovery making an in vitro diagnostic device possible and inexpensive. 
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3.12 Future Directions 
A method for developing multi-ligand based protein capture agents that can 
potentially replace the current standard, antibodies, is described and demonstrated in this 
thesis. The approach is now being applied towards the development of branched capture 
agents.  Branched peptides can emulate the effect of the variable region within a folded 
immunoglobulin (antibody), while maintaining a fairly low molecular weight (which 
reduces cost and production time).  Branched multi-ligand capture agents, like linear 
capture agents, can exhibit stability in various environments in which antibodies and 
natural polypeptides are not stable.    
Protein catalyzed multi-ligand capture agents can potentially be utilized for 
standard assays in either laboratory or clinical settings. The standard assays fall into two 
classes:  label-free and sandwich assays.  In both assays, antibodies are the mostly 
commonly utilized protein capture agents.  Multi-ligand capture agents will be tested as a 
replacement for antibodies in such traditional antibody-based assays.  Prior to the 
selection process, multi-ligand capture agents can be designed with functional groups that 
promote specific surface attachment and orientation that would be compatible with these 
assay formats.  Creating capture agents for detecting and/or separating one or more 
targets in a complex sample (e.g., blood) with high affinity and specificity will allow 
diagnosis, patient monitoring, and selection of treatment options to patients. 
Multiparameter assays can also be performed with the multi-ligand capture agents for 
proteomic analysis, tissue analysis, serum diagnostics, biomarker, serum profiling, 
multiparameter cell sorting, single cell studies, etc. We are currently translating our 
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approach to many cancer relevant protein biomarkers, including proteins with post-
translational modifications such as phosphorylation and glycosylation. 
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Figure A1. Structures of the twenty d-amino acids (side groups are denoted in red) 
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Appendix B.  Complete Structures of Biligands and Triligands 
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Figure B1.  Triligand (Mol. Wt. 3045.72) 
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Figure B2.  Triligand, biotin conjugate (Mol. Wt. 3475.29) 
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Figure B3.  Biligand Anchor, deprotected (Mol. Wt.: 2131.61) 
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Figure B4.  Biligand Anchor, fully protected (Mol. Wt.: 2732.30) 
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Figure B5.  Biligand Anchor, biotin conjugate (Mol. Wt.: 2651.26) 
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Figure B6.  Biligand kwlwGl-Tz2-kfwlkl (Mol. Wt.: 1993.49) 
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Figure B7.  Biligand lklwfk-Tz5-kiwiG (Mol. Wt.: 1807) 
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Appendix C.  
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